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1. ABBREVIATIONS  
11β-HSD1 11β-hydroxysteroid dehydrogenase type 1 
7-oxoLCA 7-oxolithocholic acid 
7-oxoDCA 7-oxodeoxycholic acid 
BA(s) Bile acid(s) 
BACS Bile acid-CoA synthase 
CA Cholic acid 
CDCA Chenodeoxycholic acid 
FXR Farnesoid X receptor 
GC(s) Glucocorticoid(s) 
GR Glucocorticoid receptor 
GRE Glucocorticoid response elements 
G-7-oxoLCA Glyco-7-oxolithocholic acid 
H6PDH Hexose-6-phosphate dehydrogenase 
NADPH Nicotinamide adenine dinucleotide phosphate 
NRF2 Nuclear factor (erythroid-derived 2)-like 2 
PGC1α Peroxisome proliferator-activated receptor-γ coactivator-1α 
T-BAs Tauro-conjugated bile acids 
T-7-oxoLCA Tauro-7-oxolithocholic acid 
VLCS Very long-chain coenzyme A synthetase 
VLCSH2 Very long-chain acyl-CoA synthetase homolog 2 
WT Wild-type 
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2. SUMMARY 
Bile acids (BAs) are important modulators of metabolic functions such as lipid, 
triglyceride and glucose homeostasis. Intrahepatic accumulation of BAs is known to 
cause liver injury in cholestatic conditions, where normal trans-hepatic BA flow is 
impaired due to pathological conditions or induced by toxic drugs. Therefore, it is 
important to understand the mechanisms of BA homeostasis regulation and to identify 
novel players and characterize their functions. The main goal of the present work was to 
investigate the impact of altered hepatic glucocorticoid activation by the enzyme 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) on BA homeostasis and to unravel 
the mechanisms of adaptations in a scenario of impaired 11β-HSD1 function. In order to 
achieve this goal, we developed and validated an ultra-performance liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS) method for the 
quantification of a total of 24 BAs, including 11 unconjugated, 6 glycine-conjugated and 
7 taurine-conjugated BAs, in biological matrices (serum/plasma and tissues) and cell 
culture supernatants. This method was validated and applied in a side project in which 
potential time-dependent changes of BAs in plasma from sham-operated and 
uninephrectomized male Sprague-Dawley rats were investigated. Several primary and 
secondary BAs were transiently elevated one week after uninephrectomy, followed by 
normalization thereafter. Using liver microsomal preparations and recombinant enzyme 
we then tested whether 11β-HSD1, in addition to its well-known role in the conversion of 
inactive to active glucocorticoids, is able to reduce 7-oxo BAs. We found that human 
11β-HSD1 reduces the secondary BA 7-oxolithocholic acid (7-oxoLCA) mainly to 
chenodeoxycholic acid (CDCA) and to lesser amount to ursodeoxycholic acid (UDCA). 
11β-HSD1 exclusively catalyzed the oxoreduction of 7-oxoLCA, in contrast to its role in 
the interconversion of glucocorticoids. The enzyme also metabolized 7-oxoLCA-glycine 
and -taurine conjugates. Furthermore, we compared 7-oxoLCA metabolism by human 
11β-HSD1 with that of other species, including canine, guinea-pig, rat, mouse and 
hamster and we observed species-specific differences. While recombinant mouse and 
rat 11β-HSD1 converted 7-oxoLCA to equivalent amounts of CDCA and UDCA, the 
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hamster and canine enzymes were stereoselective, producing mainly CDCA similar to 
the human enzyme. Surprisingly, guinea-pig 11β-HSD1 did not reduce 7-oxoLCA. The 
analysis of circulating BA profiles of several species confirmed earlier observations by 
other investigators, that 7-oxoLCA and its glycine-conjugated (G-7-oxoLCA) metabolite 
are abundant BAs in guinea-pigs compared with other species. These findings suggest 
that the lack of 11β-HSD1 oxoreductase activity on 7-oxoLCA in guinea-pigs is 
responsible for its elevated circulating levels. Next, we hypothesized that 7-oxoLCA 
might be a biomarker of impaired 11β-HSD1 activity. Analysis of BAs in serum from 
liver-specific 11β-HSD1 deficient mice revealed 18-, 47- and 7-fold elevation of 7-
oxoLCA, its taurine and glycine conjugates compared with wild-type mice, respectively. 
In addition, 7-oxoLCA and its taurine conjugate were 2- and 6-fold elevated in liver from 
liver-specific 11β-HSD1 deficient mice. Moreover, BA profiles in serum and liver of liver-
specific 11β-HSD1 deficient mice indicated a disturbed BA homeostasis. Circulating and 
intrahepatic levels of several unconjugated BAs species were up to 16-fold significantly 
elevated in liver-specific 11β-HSD1 deficient compared with wild-type mice. To pinpoint 
the molecular mechanism of altered BAs profiles, gene expression analysis was 
performed. The results suggest FXR-dependent decrease of BA synthesis, a 
compensatory effect to counteract the intrahepatic accumulation of BAs. In addition, the 
enzymes responsible for BA conjugation with coenzyme A, an intermediate step in BAs 
amidation, named  VLCS and VLCSH2 displayed significantly lower expression levels in 
liver from liver-specific 11β-HSD1 deficient compared with wild-type mice. The 
decreased BA conjugating machinery in the liver of liver-specific 11β-HSD1 deficient 
mice may account for the elevated intrahepatic levels of unconjugated BAs observed. 
Moreover, the expression of OATP4, a basolateral BA transporter responsible for the 
uptake of unconjugated BAs from the circulation into hepatocytes presented reduced 
expression levels and may account for the significant elevation of several circulating 
unconjugated BAs found in liver-specific 11β-HSD1 deficient mice.  
In conclusion, we demonstrated an important role of 11β-HSD1 in the oxoreduction on 
7-oxoLCA and provided evidences that 7-oxoLCA its taurine conjugate are functional 
biomarkers of impair 11β-HSD1 activity. Circulating concentrations of these 7-oxo BAs 
may find application in the assessment of the therapeutic efficacy of 11β-HSD1 
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inhibitors. Moreover, we described for the first time the impact of intrahepatic 
glucocorticoid regeneration deficiency on BA homeostasis in mice. Our findings indicate 
that 11β-HSD1 is an important modulator of BAs homeostasis, and potential 
disturbances of BA homeostasis must be taken into account when assessing the safety 
of 11β-HSD1 inhibitors, with particular attention to cholestatic patients and patients 
receiving combined therapeutic regimens with drugs known to induce liver injury.
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3. INTRODUCTION 
A short historical overview of the research on BAs with a focus on their physiological 
properties is presented. Then, the biochemistry of BA metabolism, including pathway of 
synthesis, conjugation and transporters will be discussed briefly, followed by an 
overview of the key modulators of BA homeostasis. Finally, the goals and objective of 
this PhD thesis will be introduced. 
3.1  BILE ACID RESEARCH, A HISTORICAL OVERVIEW 
BAs are together with cholesterol, phospholipids and bilirubin the main components of 
bile (Trauner and Boyer 2003). Although, it took until 1848 when Prof Adolph Strecker 
finally succeeded in isolating the two most abundant acids taurocholic acid and 
glycocholic acid from ox-gall, the research on bile constituents started at much earlier 
stage with the research of Prof Leopold Gmelin, Prof  Luis Jacques Thénard  and Prof 
Jöns Jacob Berzelius (Wieland 1928). In 1885, Prof Mylius discovered choleic acid, an 
acid very similar in composition to desoxycholic acid (DCA), which was discovered later 
in 1886 (Wieland 1928). It was found, however, that choleic acid was not a new 
chemical entity, but an association of fatty acids such as stearic acid, palmitc acid, oleic 
acid to desoxycholic acid (Wieland 1928). The association of fatty acids with 
desoxycholic acid was of such intensity that no dissociation into constituents occurred 
during salt formation or dissolution (Wieland 1928). These additive properties of 
desoxycholic acid were further elucidated in following experiments and showed they 
were not restricted to fatty acids, but it was found that hydrocarbons, alcohols, esters, 
and phenols could also bind to desoxycholic acid (Wieland 1928). Moreover, the alkali 
salts of desoxycholic acid, and also those of cholic acid and its conjugates are able to 
absorb lipophilic substances such as cholesterol, naphthalene, camphor, alkaloids and 
others (Wieland 1928). These initial studies provided the basis for the assumption of a 
potential physiological role of the bile to enable the diffusion of insoluble substances 
through the intestinal cells, by emulsifying them as soluble choleinates (Wieland 1928). 
In 1927, Prof Heinrich Otto Wieland was awarded the Nobel Prize in Chemistry for his 
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work on BAs, which clarified the mechanism by which bile plays a role in the absorption 
of food in the intestine and for performing structural studies of BAs. 
3.2  BILE ACID METABOLISM  
3.2.1 SYNTHESIS AND CONJUGATION 
BAs are synthesized from cholesterol in the liver and secreted from hepatocytes into the 
bile canaliculi and thereafter stored in the gall bladder (Thomas, Pellicciari et al. 2008). 
Importantly, the pathway for BA synthesis is the primary pathway for cholesterol 
catabolism and approximately 500 mg of cholesterol are converted into BAs every day 
by the adult liver (Russell 2003; Thomas, Pellicciari et al. 2008). After food intake, BAs 
are delivered into the lumen of the small intestine where they act as emulsifiers of 
dietary lipids, cholesterol and fat-soluble vitamins, which are incorporated into 
lipoproteins and transported to the liver (Russell and Setchell 1992). About 95% of BAs 
delivered to the small intestine are reabsorbed in the gut and only approximately 5% 
eliminated by the faeces (Russell 2003). The BAs eliminated are resynthesized in the 
liver through a pathway that involves at least 17 different enzymes (Russell 2003). The 
final products of this pathway are known as primary BAs: cholic acid (CA) and 
chenodeoxycholic (CDCA) acid in rats and humans, and β-muricholic acid in mice. After 
reaching the intestine, the chemical diversity of the BA pool is extensively broadened by 
the actions of anaerobic bacteria, which convert BAs into several secondary and tertiary 
compounds, hence guarantee a repertoire of hydrophobic entities needed for a 
complete solubilisation of nutrients  (Hylemon and Harder 1998). BA synthesis involves 
several steps, which can be distinguished as follows: 1) modification of the ring 
structure of cholesterol, 2) further modifications to the ring structure,  3) oxidation and 
shortening of the side chain, and 4) conjugation of the BA with an amino acid (Russell 
2003) (please refer to Figure 1 for a simplified scheme of BA biosynthesis). There are 
two pathways through which cholesterol is fluxed to form BAs: 1) the classic pathway 
(neutral, accounting for 75% of total BA pool) and 2) the alternative pathway (acidic, 
accounting for the remaining 25% of BAs) (Russell and Setchell 1992; Russell 2003). 
The two main products of this pathway are CA and CDCA (Russell 2003). Cholesterol 
INTRODUCTION 
 
7 
 
7α-hydroxylase is the first and rate-limiting enzyme of the classical pathway and is 
responsible for most of total BA synthesis (Ishibashi, Schwarz et al. 1996; Schwarz, 
Lund et al. 1996), whereas sterol-27-hydroxylase is the first enzyme of the alternative 
pathway. Interestingly, 27-hydroxylase can also hydroxylate cholesterol at carbons 24 
and 25 to from 24- and 25-hydroxycholesterol, respectively (Lund, Björkhem et al. 1993) 
(Schwarz, Russell et al. 1998; Schwarz, Russell et al. 2001). Thereafter, oxysterols are 
7α-hydroxylated by the CYP7B1 oxysterol 7α-hydroxylase (Martin, Reiss et al. 1997; 
Schwarz, Lund et al. 1997) or by CYP39A1, which remains a liver microsomal enzyme 
poorly characterized (Russell 2003). 
Ring structure modifications take place on 7α-hydroxylated intermediates derived from 
cholesterol and 7α-hydroxylated oxysterols which are converted into their 3-oxo, ∆4 
forms by microsomal 3β-hydroxy-∆5-C27-steroid oxidoreductase (HSD3B7) (Russell 
2003). The reaction involves isomerization of the double bond from the 5 to the 4 
position and the oxidation of the 3β-hydroxyl to a 3-oxo group (Wikvall 1981; Furster, 
Zhang et al. 1996). The products of the last reaction can enter two routes: 1) the 
intermediate may be 12α-hydroxylated by microsomal CYP8B1 leading to CA formation 
(Li-Hawkins, Gafvels et al. 2002) and 2) the intermediate might escape 12α-
hydroxylation and will be 5β-reduced by AKR1D1 (∆4-3-oxosteroid 5β-reductase, a 
member of the aldo-keto reductases family) (Russell 2003) to form CDCA (Russell 
2003). The last reaction of ring modification involves reduction of the 3-oxo group to an 
alcohol in the alpha stereoconfiguration and is catalyzed by 3α-hydroxysteroid 
dehydrogenase (AKR1C4) (Usui, Okuda et al. 1994), another member of the aldo-keto 
reductase family. The products of reactions of ring structure modification subsequently 
undergo progressive oxidation and shortening of the sterol side-chain. The first reaction 
in this series is catalyzed by 27-hydroxylase, which hydroxylates carbon 27, then 
oxidizes it to an aldehyde and subsequently to a carboxylic acid (Andersson, Davis et 
al. 1989; Dahlbäck and Holmberg 1990; Pikuleva, Babiker et al. 1998). These oxidized 
BA intermediates exit the mitochondria and are subsequently activated to their 
coenzyme A derivatives before side chain cleavage via peroxisomal β-oxidation. The 
first reaction is catalyzed by BA coenzyme A ligase (also known as BA coenzyme A 
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synthetase, BACS). This reaction can be accomplished by two enzymes: 1) very long-
chain coenzyme A synthetase (VLCS) (a 620 amino acid protein of the endoplasmic 
reticulum and peroxisome and 2) very long-chain acyl-coenzyme A synthetase homolog 
2 (VLCSH2) (Steinberg, Mihalik et al. 2000; Mihalik, Steinberg et al. 2002; Inoue, Yu et 
al. 2004). After activation of intermediates through BA ligase, the 25(R) isomers are 
converted into their 25(S) isomers by 2-methylacylcoenzyme A racemase, an enzyme 
localized in mitochondria and peroxisomes (Amery, Fransen et al. 2000; Kotti, 
Savolainen et al. 2000). Following this reaction, the products are next further 
dehydrogenated by FAD-containing peroxisomal branched chain acyl-coenzyme A 
oxidase to form 24,25-trans-unsaturated products (Russell 2003). There are two acyl-
coenzyme A oxidases in humans and mice (ACOX1 and ACOX2). Interestingly, human 
and mouse are catalytically similar, whereas the rat enzymes have different substrate 
specificities (Van Veldhoven, Vanhove et al. 1992). The next step in the biosynthesis of 
BAs involves hydration  and oxidation at the ∆24 bond and is catalyzed by the D-
bifunctional protein (a complex peroxisomal enzyme of 736 amino acids) (Baes, Huyghe 
et al. 2000). The final step in the oxidation of the side chain is performed by peroxisomal 
thiolase 2, which cleaves the C24-C25 bond to form propionyl-coenzyme A and a C24-
coenzyme A BA intermediate (Kannenberg, Ellinghaus et al. 1999). 
The final stage of BA biosynthesis involves the amidation usually of glycine and taurine, 
to carbon 24. This reaction is catalyzed by peroxisomal BA coenzyme A: amino acid N-
acyltransferase enzyme (Solaas, Ulvestad et al. 2000). Conjugation is an efficient 
process as more than 98% of BAs synthesized in liver are amidated (Russell 2003). 
Interestingly, there are species-dependent differences as to the substrates of the N-
acyltransferase enzyme between human and mice. While the human enzyme accepted 
BA coenzyme A thioester, taurine and glycine, the mouse enzyme displayed a 
preference to taurine (Falany, Johnson et al. 1994; Falany, Fortinberry et al. 1997). The 
conjugation of BAs increases their amphipathicity thus enhancing their solubility, and 
also making them impermeable to cells membranes (Meier 1995). 
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Figure 1. Simplified scheme of the BA synthesis pathway. Adapted from (Thomas, 
Pellicciari et al. 2008). 
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3.2.2 BILE ACID TRANSPORT SYSTEMS 
Owing to the fact that conjugated and free BAs are not able to cross membranes 
(Russell 2003), dedicated transport systems are required to enable BA flow into an out 
of cells.  
3.2.2.1 HEPATIC TRANSPORTERS 
The active transport of BAs from blood into the bile represents the major driving force 
for bile flow (Trauner and Boyer 2003). The hepatocyte is a polarized cell with 
basolaterol (sinusoidal) and apical (canalicular) membrane domains (Figure 2). Overall, 
BA transporters in the liver include those involved on BA uptake, hepatocyte efflux and 
canalicular efflux. Hepatic uptake transport starts at the basolateral membrane, which 
faces the portal blood plasma via the fenestrae of the sinuidal endothelial cells and the 
space of Disse. After uptake into hepatocytes, BAs diffuse to the canaliculi for 
subsequent excretion. This step is considered the rate-limiting step of bile secretion 
since transport occurs against a high concentration gradient into the bile (Trauner and 
Boyer 2003). It is generally assumed that BA concentrations within hepatocytes are in 
the micromolar range, whereas canalicular concentration are as much as 1000-fold 
higher (Stieger, O´Neil et al. 1992).  
Hepatic uptake transporters: The uptake of BAs occurs against a 5- to 10-fold 
concentration gradient between the portal blood and the hepatocyte and is mediated by 
two mechanism, sodium-dependent and independent systems (Nathanson and Boyer 
1991). Under normal conditions, BAs are removed from portal blood predominantly by 
zone 1 (periportal) hepatocytes (Jones, Hradek et al. 1980; Groothuis, Hardonk et al. 
1982). In this zone, the major hepatic uptake system includes the high-affinity Na+-
dependent BA transporter NTCP (SCLA1) and a family of multi-specific organic anion 
transporters (OATPs; SCL21A) that are able to mediate Na+-independent BA uptake. 
The major uptake transporters are introduced as follows: 
1) Sodium-dependent uptake via NTCP: The Na+-dependent system is responsible 
for the uptake of >80% of conjugated taurocholate and <50% of unconjugated 
cholate (Kullak-Ublick, Stieger et al. 2000; Meier and Stieger 2002). Due to the 
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fact that BAs are extensively conjugated, NTCP is the most relevant sodium-
dependent BA uptake system (Hagenbuch, Scharschmidt et al. 1996). The 
transporter is localized exclusively at the basolateral membrane of differentiated 
mammalian hepatocytes and its expression is restricted to hepatocytes 
(Ananthanarayanan, Ng et al. 1994; Stieger, Hagenbuch et al. 1994). It 
transports all physiological BAs (e.g.  taurocholate, glycocholate, 
taurodeoxycholate, tauroursodeoxycholate), although its transport activity is 
highest for the conjugated dihydroxy and trihydroxy BAs (Meier, Eckhardt et al. 
1997; Kullak-Ublick, Stieger et al. 2000; Meier and Stieger 2002).  
2) Sodium-independent uptake via OATPs. In contrast to sodium-dependent BA 
uptake, the OATPs consist of several different gene products, are sodium-
independent and display specificity for a large range of substrates not only 
including conjugated and free BAs, but also bromosulfophthalein (BSP), bilirubin, 
4,4′-diisothiocyanostilbene-2,2′-disulfonic acid (DIDS), cardiac glycosides, 
steroids, linear and cyclic peptides, mycotoxins, organic cations, and various 
pharmaceuticals  such as paravastatin (Meier, Eckhardt et al. 1997; Kullak-
Ublick, Stieger et al. 2000; Meier and Stieger 2002; Trauner and Boyer 2003). 
Nevertheless, it is generally accepted that sodium-independent transport systems 
are quantitavely not as significant as sodium-dependent uptake. (Kullak-Ublick, 
Stieger et al. 2000). OATP1 is a basolateral transporter not only expressed in the 
liver, but also on the apical membrane of the kidney proximal tubular cells, and 
choroid plexus epithelial cells (Bergwerk, Shi et al. 1996; Angeletti, Novikoff et al. 
1997).  Functionally, OATP1 transports taurocholic acid, cholic acid, glycocholic 
acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid, taurodeoxycholic 
acid, taurohyodeoxycholic acid and also a wide range of other substrates (Meier, 
Eckhardt et al. 1997; Kullak-Ublick 1999; Kullak-Ublick, Stieger et al. 2000; Meier 
and Stieger 2000; Meier and Stieger 2002). Studies using oocytes injected with 
total rat liver mRNA revealed that OATP1 is responsible for 80% of sodium-
independent taurocholate uptake (Hagenbuch, Scharschmidt et al. 1996). In 
contrast to OATP1, OATP2 is expressed in the retina, in endothelial cells of the 
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blood-brain barrier and on the basolateral membrane of hepatocytes and on 
epithelial cells in the choroid plexus (Gao, Stieger et al. 1999; Reichel, Gao et al. 
1999; Soroka, Lee et al. 2001). OATP2 is predominantly expressed in 
perivenous/pericentral hepatocytes, in contrast to OATP1 whose expression is 
homogenously distributed throughout the liver (Kakyo, Sakagami et al. 1999; 
Reichel, Gao et al. 1999). With regard to substrate specificity, OATP2 is similar to 
OATP1, with similar affinities to BAs such as taurocholate and cholate. The third 
family member is OATP4, which similarly to OATP1 and 2 is a multi-specific 
transporter including taurocholate and several other substrates (Cattori, 
Hagenbuch et al. 2000); however, a role in the transport of unconjugated BAs 
has also been proposed (Csanaky, Lu et al. 2011). 
Basolateral efflux transporters: They are responsible to remove BAs from the 
hepatocyte back into sinusoidal blood and are induced under cholestatic conditions. 
Major transporters in this category belong to the multidrug resistance subfamily such as 
MRP3, MRP4, and also organic solute transporter - OSTα/β. Originally, it was believed 
that MRP3 plays a role in BA efflux. It was then demonstrated that MRP3 knockout mice 
have no differences in serum BA concentrations and hepatic injury after bile duct 
ligation compared with wild-type controls (Belinsky, Dawson et al. 2005; Zelcer, 
Wetering et al. 2006). Moreover, human MRP3 transports BAs only with low affinity 
(Akita, Suzuki et al. 2002). On the other hand, evidence pointed out that MRP4 might 
have a protective role on hepatocytes due to the fact that cholestasis induced by bile 
duct ligation in MRP4 knockout mice resulted in aggravated liver toxicity as compared 
with bile duct ligated wild-type controls (Mennone, Soroka et al. 2006). Moreover, upon 
cholestatic conditions MRP4 expression was shown to be elevated in human and rat 
livers (Denk, Soroka et al. 2004; Gradhand, Lang et al. 2007).  
The contribution of organic solute transporters-α/β (OST) to the adaptive response to 
cholestatic liver injury has been examined by OST-α gene deletion in mice (Soroka, 
Mennone et al. 2010). Surprisingly, OST-α deficiency resulted in a substantial 
attenuation of cholestatic hepatic injury, which was mediated by an elevated urinary 
excretion of BAs concomitantly with an increased expression levels of MRP3 and MRP4 
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in the liver (Soroka, Mennone et al. 2010). Although these findings suggest a 
participation of OST-α/β in hepatic BA transport, further studies are warranted to 
elucidate their physiological relevance in this organ (Kock and Brouwer 2012).  
Canalicular efflux transport: BA transport is carried out by ATP-dependent proteins of 
the ABC transporter superfamily, e.g. multidrug-resistance proteins (MDRs) and MRPs. 
Major transporters in this category includes the bile salt export pump (BSEP), P-
glycoprotein (P-gp, MDR1a/1b) and the multidrug resistance protein 2 (MRP2). BSEP is 
considered the major canalicular bile salt transport system and is expressed exclusively 
in the canalicular membrane of hepatocytes (Kock and Brouwer 2012). BSEP presents 
a narrow substrate spectrum and is thus primarily responsible for the transport of 
monoanionic, conjugated BAs such as taurochenodeoxycholic acid, taurocholic acid, 
taurodeoxycholic acid, and glycocholic acid. In humans, BSEP deficiency results in 
progressive familial intrahepatic cholestasis type 2 (PFIC2), a fatal liver disease with 
greatly reduced bile flow (Strautnieks, Bull et al. 1998). However, in mice BSEP 
knockout leads to nonprogressive, persistent intrahepatic cholestasis manifested by 
significantly less severity than PFIC2, suggesting an alternative BA canalicular efflux 
transport in mice compensates for the loss of BSEP. These findings led to the discovery 
that multidrug resistance (MDR) transporters such as MDR1a and MDR1b can 
compensate for the loss of BSEP in mice (Wang, Salem et al. 2001; Wang, Chen et al. 
2009). Moreover, MDR1a was shown to transport BAs in mice; however, with a lower 
affinity (Lam, Wang et al. 2005). On the other hand, MDR2-null mice exhibited similar 
BA excretion into bile compared with wild-type mice suggesting a minor role in BA 
transport. Nevertheless, its importance on biliary excretion of phospholipids in the 
canalicular membrane suggests a role in protecting the biliary tree from BA toxicity by 
forming mixed phospholipid-BA micelles (Elferink, Tytgat et al. 1997). 
MRP2 is an organic anion transporter expressed in the apical (canalicular) membrane of 
hepatocytes, involved in the transport of bile salt sulfates conjugate such as 
taurolithocholate-3-sulfate, but not monoanionic bile salts such as taurocholate (Gerk 
and Vore 2002). MRP2 is involved also in the biliary transport of other endogenous 
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substrates such as glutathione, bilirubin glucuronide and a broad range of exogenous 
compounds (Jemnitz, Heredi-Szabo et al. 2010).  
3.2.2.2 INTESTINAL TRANSPORTERS 
After reaching the intestine, BAs are extensively reabsorbed and transported back to 
the liver via the enterohepatic circulation. It is generally accepted that the BA transport 
in the enterocytes consists of three major components: 1) apical uptake of conjugated 
BAs in terminal ileum via a sodium-dependent mechanism; 2) intracellular BA transport 
in the enterocytes mediated via cytosolic BA-binding protein (IBABP) and 3) anion 
exchange mechanism for the basolateral efflux of BAs from enterocytes.  
Apical transport: Apical transport in the enterocyte occurs via mainly three 
mechanisms: 1) passive diffusion of unconjugated BAs in small and large intestine; 2) 
uptake of BAs in the terminal ileum via a sodium-dependent mechanism and 3) sodium-
independent anion exchange mechanism in proximal jejunum (Klaassen and Aleksunes 
2010). The well characterized ASBT (Apical sodium bile acid transporter, SLC10A2) is 
expressed on the apical surface of ileal enterocytes and transports conjugated and 
unconjugated BAs, with higher affinity for dihydroxy BAs such as CDCA and DCA 
compared with trihydroxy BAs such as cholate, taurocholate, and glyco-cholate 
(Craddock, Love et al. 1998). Faecal BA excretion is increased in ASBT-null mice, 
leading to a reduced total BA pool (Dawson, Haywood et al. 2003). Moreover, several 
loss-of-function mutations in the ASBT gene cause primary BA malabsorption that is 
characterized by diarrhea, fat malabsorption, and malnutrition (Wong, Oelkers et al. 
1995; Oelkers, Kirby et al. 1997).  
After transport across the enterocyte membrane, BAs are bound to IBABP, which 
belongs to a family of intracellular lipid-binding proteins that reversibly bind BAs and 
other lipids (Trauner and Boyer 2003). Its expression is limited to the ileum, with low 
expression found in cholangiocytes (Lin, Kramer et al. 1990). However, further studies, 
including the generation of IBABP-null mice, would shed light on the physiological 
importance for BA homeostasis.  
INTRODUCTION 
 
15 
 
Apical efflux transporter in the intestine: MDR1a/Pgp is expressed at the apical 
surface of enterocytes (Panwala, Jones et al. 1998) and plays a role in effluxing drugs 
from enterocytes back into the intestinal lumen and thereby affecting absorption of orally 
administration medication (Klaassen and Aleksunes 2010). Similar, to the liver, MRP2 
exerts apical efflux transport of BAs in enterocytes. 
Basolateral efflux transporters in the intestine: Similar to the liver, OST-α and OST-
β are responsible to efflux BAs and other substrates such as conjugated steroids across 
the basolateral membrane in the intestine (Seward, Koh et al. 2003). OST-α-null mice 
presented with hypertrophy of the small intestine and a reduced BA pool, reduced 
serum BAs, reduced cholesterol and triglycerides levels, and exhibited several 
compensatory gene expression changes, including higher intestinal, hepatic and renal 
MRP3 and lower CYP7A1 expression levels (Ballatori, Fang et al. 2008). Furthermore, 
combined loss of OST-α and MRP3 in female OST-α/MRP3-null mice results in 
disrupted transileal transport of taurocholic acid (Rao, Haywood et al. 2008). The 
current known substrates of OST-α/β includes the major species of BAs such as glycine 
and taurine conjugates of cholic acid, deoxycholic acid, chenodeoxycholic acid, and 
ursodeoxycholic acid (Ballatori, Christian et al. 2005).  
3.2.2.3 RENAL TRANSPORTER   
BAs which escape first-pass clearance by the liver (10 to 50%, depending on the BA 
species) are filtered at the glomerulus and reabsorbed in the proximal convoluted tubule 
(Wilson, Burckhardt et al. 1981). Under normal conditions, urinary BA losses are 1-2% 
of total renal BA input; however, renal elimination of sulfated and glucuronidated BAs 
become an important adaptive mechanism under cholestatic situations (Trauner and 
Boyer 2003). Similar to the ileocytes, renal proximal tubule epithelium expresses the 
ASBT and OST-α/β (Ballatori, Christian et al. 2005), which guarantee the efficient renal 
influx of BA back into the circulation. On the other hand, apical efflux transporters such 
as MRP2, MRP4 and MDR1b are mainly responsible for renal secretion of chemical into 
urine (Klaassen and Aleksunes 2010). 
 
INTRODUCTION 
 
16 
 
 
Figure 2. Overview of the bile acid transport system in hepatocytes, ileocytes and tubule 
cells is shown. Arrows indicate BA flow. glucBA: glucoronidated-BA, SBA: sulfated-BA; 
TBA: tauro-BA; GBA: glyco-BA. (Adapted from (Thomas, Pellicciari et al. 2008)). 
3.2.3 BIOTRANSFORMATION OF BAS 
During the enterohepatic circulation, primary BAs escaping ileal transport, 
approximately 400-800 mg/day, are substrates for intense bacterial biotransformation 
and structural modification by the action of facultative and anaerobic bacteria to give 
rise to secondary BAs, therefore broadening their chemical structures and properties 
(Ridlon, Kang et al. 2006). Biotransformation reactions consists mainly of deconjugation 
by bile salt hydrolases (BSH), hydroxyl group dehydrogenation/epimerization at position 
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3-, 7- and 12- by hydroxysteroid dehydrogenases (HSDs) and  dehydroxylation at 
position 7α- and 7β- (Ridlon, Kang et al. 2006).  Epimerization is the reversible change 
in stereochemistry from α to β (or vice versa) with the generation of stable oxo-bile acid 
intermediates (Ridlon, Kang et al. 2006). 3α/β-HSDs specifically catalyze the reversible, 
stereo-specific oxidation/reduction between 3oxo- and 3α- or 3β-hydroxy BAs and seem 
to favour the 3α-position (Macdonald, Hutchison et al. 1983). On the other hand, 7α-/7β- 
and 12α-/12β-HSDs  catalyze the reversible, stereospecific oxidation/reduction of the 
7α-/7β- and 12α-/12β- hydroxyl groups of BAs, respectively (Ridlon, Kang et al. 2006). 
The action of these enzymes increases the amount of β-hydroxylated BAs, which reach 
the liver via the enterohepatic circulation; however, they do not accumulate owing to 
their efficient epimerization (Ridlon, Kang et al. 2006).  In the human colon, several 
bacterial strains, including Escherichia coli, Bacteroides fragilis and Bacteroides 
intestinalis express 7-HSDs that generate 7-oxoDCA from CA and 7-oxoLCA from 
CDCA and UDCA (Macdonald, Williams et al. 1975; Fukiya, Arata et al. 2009). In spite 
of these reactions, it is generally assumed that 7α-dehydroxylation is the most important 
bacterial bile salt biotransformation in the human colon due to the fact that secondary 
BAs such as DCA and LCA predominate in human faeces and owing to the inability of 
human liver to 7α-hydroxylate these secondary BAs back to their respective primary 
forms (Ridlon, Kang et al. 2006).  
3.2.4  MAJOR REGULATORS OF BA HOMEOSTASIS  
3.2.4.1 FARNESOID X RECEPTOR (FXR) 
BAs modulate their own biosynthesis from cholesterol through mechanism of feedback 
regulation, which is controlled by the entero-hepatic system. Possibly, the first layer of 
regulation involved in this intricate regulatory mechanism involves the FXR. FXR is an 
intracellular BA sensor controlling BA homeostasis through orchestrating enterohepatic 
recycling, transport and biosynthesis of BA, thus allowing the organism to maintain a 
constant BA pool and to mediate hepatic protective responses to counteract BA 
accumulation in pathophysiological and toxicological situations (Thomas, Pellicciari et 
al. 2008; Klaassen and Aleksunes 2010). FXR is not exclusively expressed in the liver. 
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The intestine, the kidney and the adrenal cortex are also organs of abundant FXR 
expression (Bookout, Jeong et al. 2006). Some conjugated and free BAs are 
endogenous ligands that activate FXR, among them CDCA and its conjugates present 
the most potent affinity in the range of EC50 of 4.5 – 10 µM (figure 3) (Makishima, 
Okamoto et al. 1999; Parks, Blanchard et al. 1999; Wang, Chen et al. 1999). After 
activation, FXR induces the expression of the short heterodimer partner (SHP-1, 
NR0B2), an atypical nuclear receptor capable of interfering with the activity of several 
nuclear receptors such as the liver receptor homologue 1 (LRH1, NR5A2) and liver X 
receptor-α (LXR-α, NR1H3) to repress the expression of CYP7A1 and CYP8B1, two 
main enzymes in the biosynthesis of BAs (Figure 3) (Goodwin, Jones et al. 2000; Zhang 
and Chiang 2001; Brendel, Schoonjans et al. 2002; Båvner, Sanyal et al. 2005). At the 
same time, hepatic FXR activation increases BA conjugation (Pircher, Kitto et al. 2003) 
and canalicular efflux by inducing the transcription of BSEP, MDR2 and MRP2 thus 
promoting bile flow and preventing accumulation of toxic BAs in the liver (Eloranta and 
Kullak-Ublick 2005). In addition, FXR decreases hepatic BA uptake by down-regulating 
NTCP gene expression in isolated hepatocytes (Denson, Sturm et al. 2001). Therefore, 
FXR-null mice develop increased hepatic necrosis due to intrahepatic cholestasis, 
which demonstrates the importance of FXR mediated BA homeostasis (Zollner, Fickert 
et al. 2003; Cui, Aleksunes et al. 2009). In the intestine, FXR promotes expression of 
the ileal BA binding protein (I-BABP, FABP6), basolateral BA transporters OST-α/β, 
ASBT expression in mouse and human ileum, and fibroblast growth factor 19 (FGF19 or 
FGF15 in mouse), which subsequently through an autocrine and SHP-independent 
mechanism represses CYP7A1 gene in the liver (Holt, Luo et al. 2003; Houten and 
Auwerx 2004; Moschetta, Bookout et al. 2004; Inagaki, Choi et al. 2005; Sinha, Chen et 
al. 2008). Surprisingly, a recent study suggests that FGF19 autocrine signalling from the 
intestine plays a dominant role in FXR mediated CYP7A1 gene repression over the 
FXR-SHP pathway, while FXR/SHP pathway was important for supressing CYP8B1 
(Kong, Wang et al. 2012). Further studies are needed to clarify the contribution of each 
pathway in supressing BA synthesis. Overall, the collective effect of BA-mediated FXR 
is to prevent accumulation of toxic BA accumulation by stimulating BA efflux in the 
canaliculus and preventing BA uptake from the portal blood. In addition, BA 
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accumulation in the enterocytes activates FXR, which in turn represses BA absorption 
and biosynthesis (Thomas, Pellicciari et al. 2008).  
3.2.4.2 PREGNANE-X RECEPTOR (PXR) 
The role of PXR in regulating BA synthesis was identified by using the PXR agonist 
pregnenolone 16α-carbonitrile (PCN) which repressed hepatic CYP7A1 (Mason and 
Boyd 1978). In follow-up studies, these initial findings were confirmed by using PXR-
deficient mice in which PCN-mediated repression of CYP7A1 is absent (Staudinger, 
Goodwin et al. 2001). Other known direct agonists for human and murine PXR are 
lithocholic acid (LCA) and 5β-Cholestan-3α, 7α, 12α-triol (Goodwin, Jones et al. 2000). 
The effect of PXR on CYP7A1 repression seems to be mediated by HNF4α and 
PGC1α, which are required for CYP7A1 gene transcription (Bhalla, Ozalp et al. 2004). 
On the other hand, activation of PXR in intestinal cells was shown to induce FGF15 
expression and a PXR response element is found in FGF15 (Wistuba, Gnewuch et al. 
2007). Interestingly, a recent study showed that PXR-null mice fed a lithogenic diet had 
a higher susceptibility to develop cholesterol gallstones, an effect which may be related 
to decreased CYP7A1 gene expression, and consequently a reduced BA pool (He, 
Nishida et al. 2011). Moreover, PXR induces CYP3A enzymes, which are responsible 
for BA hydroxylation, BA conjugating enzymes such as SULT2A1 and UGTs, 
transporters such as MRP2 and OATP2, which strongly suggests that PXR activation is 
part of the organism´s adaptive response to reduce the burden of excessive BA levels 
and counteract BA toxicity (Staudinger, Goodwin et al. 2001; Kliewer and Willson 2002). 
Supporting this notion is the fact that PXR-null mice are more susceptible to 
hepatotoxicity of LCA, bile duct ligation and numerous experimental forms of cholestasis 
(Staudinger, Goodwin et al. 2001; Stedman, Liddle et al. 2005). In humans, rifampicin 
treatment has been used to reduce pruritus associated with cholestasis, an effect 
believed to be mediated by PXR (Hofmann 2002). 
3.2.4.3 VITAMIN D RECEPTOR (VDR) 
Several lines of evidence revealed that the VDR may act as an intestinal BA sensor, 
which protects the intestine from BA toxicity. BAs, particularly LCA, is an endogenous 
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VDR ligand, besides 1α,25-dihydroxyvitamin D3 (Makishima, Lu et al. 2002).  Examples 
of functions of VDR in intestinal cells include the induction of CYP3A, SULT2A1, MRP3 
and ASBT (Thummel, Brimer et al. 2001; Chen, Ma et al. 2003; Chatterjee, Echchgadda 
et al. 2005; McCarthy, Li et al. 2005). Similarly, in human hepatocytes treatment with 
VDR agonists induces the expression of VDR target genes, including CYP3A, CYP2B 
and CYP2C; however, further studies are needed to elucidate the role of VDR in the 
liver. In culture hepatocytes and using VDR-null mice, there is evidence suggesting that 
VDR agonists are able to repress CYP7A1 expression, possibly through the FGF15 
pathway since FGF15-null mice failed to repress CYP7A1 upon 1α,25-dihydroxyvitamin 
D3 treatment (Han and Chiang 2009; Schmidt, Holmstrom et al. 2010). Despite these 
observations, the role of VDR in repressing BA synthesis is still controversial and further 
studies are needed to clarify its physiological and potential pharmacological applications 
(Nishida, Ozeki et al. 2009). 
3.2.4.4 NUCLEAR FACTOR-E2-RELATED FACTOR 2 (NRF2) 
Nrf2 is a transcription factor member of the basic leucine zipper family and is a crucial 
mediator of an adaptive response to counteract oxidative stress (Moi, Chan et al. 1994; 
Klaassen and Reisman 2010). Nrf2 binds to antioxidant response elements (AREs) in 
the regulatory regions of target genes and activates the transcription of genes involved 
in detoxification such as NAD(P)H quinone oxidorecutase 1 (Nqo1), heme oxidase-1, 
glutathione-S-transferase, and the glutathione synthesis enzymes glutamate cysteine 
ligases (Weerachayaphorn, Mennone et al. 2012). Moreover, increased hepatic 
expression of Nrf2-dependent Nqo-1 is seen in cholestasis following bile duct ligation 
(BDL) in mice, suggesting its activation during cholestasis (Weerachayaphorn, 
Mennone et al. 2012). Nevertheless, Nrf2-null mice do not exhibit more severe hepatic 
injury after BDL, which could be explained by the decreased expression of CYP7A1, 
CYP8B1 and ASBT, and increased CYP3A11, BSEP and OST-α mRNA expression 
levels. (Weerachayaphorn, Mennone et al. 2012). These findings suggest an important 
role of Nrf2 in the regulation of BA homeostasis in liver and intestine.  
INTRODUCTION 
 
21 
 
3.2.4.5 GLUCOCORTICOID RECEPTOR AND 11Β -HYDROXYSTEROID 
DEHYDROGENASE TYPE 1 
The glucocorticoid receptor (GR) is a ubiquitously expressed nuclear receptor, which 
regulates a plethora of physiological processes (Odermatt and Gumy 2008; 
Ramamoorthy and Cidlowski 2013). The GR is essential for the modulation of the 
immune system, lipid synthesis, carbohydrate metabolism, stress response, the 
maintenance of electrolyte concentrations, blood pressure, appropriate brain functions, 
neuronal functions and cellular growth and differentiation (Odermatt and Gumy 2008; 
Odermatt and Nashev 2010). It is estimated that up to 10-20% of all genes in a higher 
organism is modulated by glucocorticoids promoting time- and tissue-specifically gene 
expression networks which fine-tune metabolic processes (John, Johnson et al. 2009; 
Ramamoorthy and Cidlowski 2013). The importance of appropriate function of GR can 
be illustrated by the fact the GR-null mice die after birth and untreated adrenalectomy is 
lethal (Cole, Blendy et al. 1995). Endogenous glucocorticoids (e.g., cortisol, 
corticosterone) and their synthetic analogs (e.g. dexamethasone, prednisolone, 
budesonide) activate GR leading to GR homodimerization and nuclear translocation 
(Ramamoorthy and Cidlowski 2013). Synthetic glucocorticoids are widely used to treat 
inflammatory and autoimmune diseases, including asthma, rheumatoid arthritis and 
numerous allergic reactions; however, long-term treatment with glucocorticoids are 
associated with hyperglycemia, liver steatosis, hyperlipidemia and insulin resistance 
through the activation of hepatic gluconeogenesis (Andrews and Walker 1999; Lemke, 
Krones-Herzig et al. 2008). Nevertheless, GR also modulates BA homeostasis in 
humans, which can be illustrated by the fact that Cushing´s patients and patients with 
chronic active hepatitis upon short-term glucocorticoids therapy with prednisolone 
presented increased serum BAs (Yamanishi, Nosaka et al. 1985; Lu, Zhang et al. 
2012). In animals models GR-mediated effects on BA handling is recapitulated by 
dexamethasone treatment in mice and rats, which present higher circulating BA levels 
as compared with control groups (Lu, Zhang et al. 2012; Rosales, Romero et al. 2013). 
Dexamethasone treatment has been shown to increase CYP7A1, CYP8B1, BSEP, 
MRP3 and MRP4, while down-regulates MDR1a and SHP gene expression levels in the 
liver of mice (Lu, Zhang et al. 2012). Interestingly, dexamethasone mediated BA 
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changes were blunted in FXR-null mice, suggesting that active FXR is essential for the 
GR-mediated effects in SHP expression and thus BA homeostasis (Lu, Zhang et al. 
2012). Furthermore, it was shown that the GR physically interacts with FXR and 
represses its transcriptional activity by recruiting C-terminal binding protein (CtBP) upon 
dexamethasone treatment (Lu, Zhang et al. 2012). Interestingly, silencing of CtBP in 
vivo using adenoviral vectors normalized hepatic BA contents upon glucocorticoids 
treatment and also SHP, CYP7A1 and CYP8B1 expression levels (Lu, Zhang et al. 
2012). Although, the mechanism of FXR repression by GR seems to be the major effect 
of glucocorticoids on BA homeostasis, the direct repression or induction of target genes 
involved in BA homeostasis by the GR has also been shown (Lu, Zhang et al. 2012). 
Moreover, the GR also play a role in hepatic and ileal BA uptake by transactivating the 
human NTCP and ASBT, respectively (Jung, Fantin et al. 2004; Eloranta, Jung et al. 
2006; Rose, Díaz et al. 2011). In addition, GR activation induces ileal and hepatic OST-
α/β expression in humans and rodents (Khan, Chow et al. 2009). In spite of these 
findings, the pharmacological approach with synthetic glucocorticoids for the elucidation 
of interactions between glucocorticoids and BA homeostasis is highly artificial since 
synthetic glucocorticoids have different properties compared with endogenous 
glucocorticoids. Depending on their concentrations, they may influence the activities of 
other nuclear receptors (Pascussi, Drocourt et al. 2000; Pascussi, Gerbal-Chaloin et al. 
2000). Moreover, differences regarding study design, treatment duration and animal 
models explain large variations and controversy emerging from these studies.  In this 
context, Rosales et  al. reported that although glucocorticoids treatment in rats induced 
BSEP, MRP2 and CYP27A1, genes coding for FXR, GR, SHP, NTCP, MRP4, CYP7A1 
and BAT were down-regulated (Rosales, Romero et al.). The observations by Rosales 
et al. are in contradiction with those of Rose et al. who reported opposite effects of 
dexamethasone treatment regarding to circulating BAs concentrations in mice (Rose, 
Díaz et al. 2011). In addition, Cheng et al. have shown that although NTCP is up-
regulated upon dexamethasone treatment in mouse liver (Cheng, Buckley et al. 2007), 
BSEP expression was not influenced, findings which are in conflict with to that of other 
investigators (Lu, Zhang et al. 2012; Rosales, Romero et al.). Experimental protocol, 
animal strain, treatment regimens and different drugs are likely to be responsible for 
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these discrepancies. On the other hand, in vitro liver models may offer a more robust 
alternative system to study the role of glucocorticoids on BA homeostasis.  
Nevertheless, culture conditions might largely influence the results. With this regard, 
Turncliff  et al. supplied 100 nM of dexamethasone (DEX) to sandwich-cultured rat 
hepatocytes and reported that DEX had no effect on OATP1a1, MRP3, MDR1a/b or 
BSEP expression levels (Turncliff, Meier et al. 2004). Intriguingly, NTCP expression was 
down-regulated, contrasting previous reports (Eloranta, Jung et al. 2006).  
Glucocorticoid action in organs and cells are not solely determined by the circulating 
concentration of active steroids, yet another layer of regulation is the one performed by 
enzymes modulating the ratio of active/inactive (cortisol/cortisone) metabolites and thus 
determine intracellular availability of active metabolites. The enzymes responsible for 
the interconversion of glucocorticoids are known to belong to the short-chain 
dehydrogenase/reductase (SDR)  family, which comprise 73 genes in humans 
(Odermatt and Nashev 2010). 11β-HSD1 (SDR26C1) is a member of the SDR 
superfamily and responsible for glucocorticoid (cortisol) regeneration in metabolically 
active tissues such as liver, adipose and skeletal muscle (Odermatt and Nashev 2010). 
A considerable number of researchers used animal models of overexpression and 
knockout of 11β-HSD1 to provide evidence for an association between the development 
of metabolic diseases and excessive glucocorticoid exposure (Tomlinson and Stewart 
2007). In addition, treatment with selective 11β-HSD1 inhibitors of transgenic and diet-
induced rat models of obesity, type 2 diabetes and atherosclerosis demonstrated 
beneficial outcomes of several metabolic parameters (Tomlinson and Stewart 2007; 
Odermatt and Nashev 2010). Currently, several pharmaceutical companies have on-
going programs in pursuit of selective inhibitors; however, several questions regarding 
the safety of such inhibitors have arisen due to “alternative” functions of 11β-HSD1, 
which include the metabolism of several endogenous and exogenous compounds such 
as 7-hydroxy- and 7-keto-DHEA, 7-oxygenated pregnenolone, 7-ketocholesterol, 7-
ketoepiandrosterone, 7-keto-5-androstane-3,17-diol, 7-oxoLCA, metyrapone, p-
nitroacetophenone, p-nitrobenzaldehyde, ketoprofen, oracin, triadimefon and the 
tobacco carcinogen nicotine-derived nitrosamine ketone (NNK) (Odermatt and Nashev 
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2010; Odermatt, Da Cunha et al. 2011). Taking this into consideration, we investigated 
in this work the role of 11β-HSD1 in BA homeostasis since 11β-HSD1 regenerates 
glucocorticoids in hepatocytes and thus may modulate the transcriptional activity of GR-
dependent genes including those responsible for the fine-tuning BA homeostasis. In 
addition, this work raises further safety questions regarding therapeutic interventions 
with 11β-HSD1 inhibitors which need to take into consideration the impact on BA 
homeostasis. To the best of our knowledge, this is the first work addressing these 
questions. In the course of this thesis, we have also discovered a novel role of 11β-
HSD1 in BA homeostasis, i.e. the metabolism of the secondary BA 7-oxoLCA, thus 
extending our knowledge of the functions of this enzyme with regard to BA 
homeostasis. 7-oxoLCA and its conjugates, deprived of apparent major physiological 
functions and toxicity may serve as biomarker of 11β-HSD1 inhibition in clinical and 
preclinical studies.     
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Figure 3. Mechanism of regulation of BA homeostasis by BAs, nuclear receptors and 
transcriptional factors (adapted from (Thomas, Pellicciari et al. 2008). 
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In this study we characterized a new function of 11β-HSD1 in the metabolism of the 
secondary BA 7-oxoLCA acid using in vitro assays. 
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In this study, we reported the development, validation and application of a method using 
UPLC-MS/MS for quantification of concentrations of multiple BAs in biological samples.   
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ABSTRACT  
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) has emerged as a promising 
therapeutic target to treat metabolic diseases; however, suitable biomarkers to assess 
its activity in vivo are still lacking. Recently, we characterized the in vitro metabolism of 
a novel substrate of 11β-HSD1 – the secondary bile acid 7-oxolithocholic acid (7-
oxoLCA). Here, we provide further in vitro and in vivo evidence for an exclusive role of 
11β-HSD1 in the oxoreduction of 7-oxoLCA. Hepatic microsomes of liver-specific 11β-
HSD1 deficient mice were devoid of 7-oxoLCA oxoreductase activity. In addition, 7-
oxoLCA and its taurine and glycine conjugates were 18- , 47- and 7-fold elevated in 
serum and 2- and 6- in liver from liver-specific 11β-HSD1 deficient mice, respectively. 
Since glucocorticoids can regulate the expression of genes involved in bile acid (BA) 
homeostasis, we assessed the impact of 11β-HSD1 deficiency on circulating and 
hepatic BA profiles in mice. We observed an accumulation of unconjugated BAs in the 
liver and serum from liver-specific 11β-HSD1 deficient mice, an effect attributable to a 
down-regulation of BA coenzyme A conjugating enzymes (VLCS and VLCSH2) and the 
reduced expression of OATP4. In conclusion, the results suggest a role of 11β-HSD1 in 
the regulation of BA homeostasis, whereby 7-oxoLCA and its taurine conjugate may 
serve as biomarkers for impaired 11β-HSD1 activity. Importantly, we found that guinea-
pig cannot reduce 7-oxoLCA, providing explanation why 7-oxoLCA is a major BA in this 
species.  
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INTRODUCTION 
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a NADPH-dependent enzyme 
facing the endoplasmic reticulum lumen and responsible for cortisol (corticosterone in 
rodents) regeneration from inactive cortisone (11-dehydrocorticosterone in rodents), 
thus mediating tissue specific exposure to active glucocorticoids (Odermatt, Arnold et al. 
1999; Odermatt, Atanasov et al. 2006). Glucocorticoid excess is implicated in the 
pathogenesis of the metabolic syndrome characterized by glucose intolerance, insulin 
resistance, dyslipidaemia and hypertension  (Tomlinson and Stewart 2007). Evidences 
from transgenic mice (knockout or overexpression of 11β-HSD1) revealed potential 
benefits of 11β-HSD1 inhibition to ameliorate obesity and the metabolic syndrome 
(Kotelevtsev, Holmes et al. 1997; Masuzaki, Paterson et al. 2001; Morton, Holmes et al. 
2001; Masuzaki, Yamamoto et al. 2003; Morton, Paterson et al. 2004; Paterson, Morton 
et al. 2004; Hughes, Webster et al. 2008; Boyle and Kowalski 2009; Hadoke, Iqbal et al. 
2009; Wamil, Battle et al. 2011). More recently, data from human phase II clinical trials 
are supporting results from animal studies, and currently several companies are 
developing selective inhibitors (Rosenstock, Banarer et al. 2010; Thomas and Potter 
2011). However, validated biomarkers of 11β-HSD1 inhibition in preclinical and clinical 
studies are still unavailable and are of great interest in order to assess the in vivo 
efficacy of therapeutic inhibitors. In this regard, circulating concentrations of 
glucocorticoids are not suitable biomarkers because they are not significantly altered in 
plasma of liver-specific 11β-HSD1 deficient and 11β-HSD1-null mice (Carter, Paterson 
et al. 2009; Lavery, Zielinska et al. 2012). Similarly, urinary 11-dehydrocorticosterone 
(11-DHC) levels are unchanged in heterozygous 11β-HSD1 deficient compared with 
wild-type mice, suggesting that 11β-HSD1 does not significantly alter systemic 
glucocorticoid levels (Abrahams, Semjonous et al. 2012). An ideal biomarker should be 
independent of mechanisms of negative feedback regulation such as control by the 
HPA axis of circulating glucocorticoids, and stress-induced fluctuations (Harno and 
White 2010; Odermatt and Nashev 2010).  11β-HSD1 has a broad substrate specificity 
and metabolizes endogenous and exogenous compounds such as 7-hydroxy- and 7-
keto-DHEA, 7-oxygenated pregnenolone, 7-ketocholesterol, 7-ketoepiandrosterone, 7-
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keto-5-androstane-3,17-diol, metyrapone, p-nitroacetophenone, p-nitrobenzaldehyde,  
ketoprofen, oracin, triadimefon and the tobacco carcinogen nicotine-derived nitrosamine 
ketone (NNK). (Maser and Bannenberg 1994; Hult, Nobel et al. 2001; Wsól, Szotáková 
et al. 2003; Hult, Elleby et al. 2004; Schweizer, Zürcher et al. 2004; Martin, Breyer-Pfaff 
et al. 2006; Muller, Pompon et al. 2006; Hennebert, Le Mée et al. 2007; Hennebert, 
Pernelle et al. 2007; Nashev, Chandsawangbhuwana et al. 2007; Kenneke, Mazur et al. 
2008). We recently identified a novel role of 11β-HSD1 in the metabolism of the 
secondary BA 7-oxoLCA (Odermatt, Da Cunha et al. 2011). 11β-HSD1 reduced 7-
oxoLCA preferentially to the 7α-hydroxylated chenodeoxycholic (CDCA) and to a lesser 
extent to the 7β-hydroxylated ursodeoxycholic acid (UDCA) (Odermatt, Da Cunha et al. 
2011).  7-oxoLCA is formed in the colon by 7α-hydroxysteroid dehydrogenation of 
CDCA and UDCA by microorganism such as Eschericha coli, Bacteroides fragilis and 
Bacteroides intestinalis (Macdonald, Williams et al. 1975; Fukiya, Arata et al. 2009). 
Thereafter, 7-oxoLCA is reabsorbed in the intestine and reaches the liver through the 
enterohepatic cycle. In this work, we provide further evidences for an exclusive role of 
11β-HSD1 in the oxoreduction of 7-oxoLCA both in vitro and in vivo. Furthermore, we 
suggest that its accumulation may serve as a potential readout of 11β-HSD1 inhibition 
in vivo. Moreover, we revealed the impact of hepatic 11β-HSD1 deficiency on BA 
homeostasis. Liver-specific disruption of 11β-HSD1 altered BA homeostasis, resulting in 
the accumulation of unconjugated BAs in the liver and serum of liver-specific 11β-HSD1 
deficient mice, a phenomenon likely mediated by the glucocorticoid receptor (GR) and 
an altered intrahepatic concentration of active glucocorticoids.  
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MATERIALS AND METHODS 
 
CHEMICALS AND REAGENTS 
Chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), [2,2,4,4-2H4]-CDCA 
(>98% isotopic purity) and [9,11,12,12-2H4]-cortisol (>98% isotopic purity) were 
purchased from Sigma-Aldrich (St. Louis, MO). 7-oxolithocholic acid (7-oxoLCA) was 
purchased from Steraloids (Newport, RI). Cell culture media were purchased from 
Invitrogen (Carlsbad, CA) and Sigma (Buchs, Switzerland). [1,2,6,7-3H]-cortisone were 
obtained from American Radiolabeled Chemicals (St. Louis, MO), [1,2,6,7-3H]-cortisol 
from Amersham Pharmacia (Piscataway, NJ) and 5H-1,2,4-triazolo(4,3-
a)azepine,6,7,8,9-tetrahydro-3- tricyclo(3·3·1·13·7)dec-1-yl (T0504) from Enamine 
(Kiev, Ukraine). Male guinea-pig liver microsomes were obtained from Celsis 
International and serum of 12-16 h fasted mice (balb/c and C57bL/6), rats (Han Wistar 
and Sprague-Dawley), canine (Canis familiaris, beagle bred), guinea-pigs (dunkin-
hartley) and hamsters (golden syrian) were obtained from Harlan (Gannat, France).  
 
REDUCTION OF 7-OXOLCA BY RECOMBINANT HUMAN 11Β-HSD1 OF 
VARIOUS SPECIES 
In order to access species-dependent differences of 7-oxoLCA metabolism by 11β-
HSD1, HEK-293 cells cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 50 units/ml penicillin, 50 μg/ml 
streptomycin and 2 mM glutamine were transiently transfected with recombinant 11β-
HSD1 from rat, mouse, human, hamster, canine and guinea-pig as described previously 
(Odermatt, Arnold et al. 1999; Schweizer, Zürcher et al. 2004; Arampatzis, Kadereit et 
al. 2005). Thereafter, cells were detached, centrifuged and pellets stored at -80°C. Cell 
pellets were resuspended in TS2 buffer (100 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 
mM MgCl2, 250 mM sucrose and 20 mM Tris/HCl, pH 7.4), sonicated and used 
immediately to measure enzyme activity. 
To determine the apparent Km and apparent Vmax of 11β-HSD1, lysates were 
incubated for 10 min at 37ºC in a total volume of 500 μl containing 500 μM NADPH and 
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7-oxoLCA at concentrations between 62.5 nM and 4 μM. Reactions were terminated by 
freezing samples in dry ice. Concomitantly, lysates were used in parallel experiments to 
assess the conversion of radiolabeled glucocorticoids. Briefly, lysates were incubated 
for 10 min at 37ºC in a total volume of 22 μl containing 200 nM and 10 nCi of [1,2–
3H]cortisone and 500 μM cofactor NADPH. Following conversion of radiolabeled 
glucocorticoids and termination of reactions by adding methanol containing 2 mM 
unlabeled cortisone and cortisol, 15 μl were spotted on Polygram SIL G-25 UV254 silica 
plates (Macherey-Nagel), plates were dried, and cortisone and cortisol were resolved 
using a solvent system of 9:1 (v/v) chloroform/methanol. The separated steroids were 
analysed by scintillation counting. The expression level in different transfection 
experiments was determined semiquantitatively by immunoblotting. Protein 
concentrations were determined by bicinchoninic acid (BCA) method. An amount of 25 
µg of total protein was resolved on 12% Bis-Tris gels (NuPage®, Invitrogen) using 1 × 
MES as buffer (Invitrogen, NuPAGE® MES SDS Running Buffer) and transferred to 
nitrocellulose membranes (iBlot®, Invitrogen). Thereafter, membranes were blocked 
with Odyssey® blocking buffer (LI-COR, Biosciences, Lincoln, NE, USA) overnight at 
4ºC. Immunoreaction was carried out with primary antibody anti-FLAG M2 (Invitrogen) 
or anti-human 11β-HSD1 antibody (Cayman Chemical, Ann Arbor) and secondary goat 
anti-mouse Alexa Fluor® 790, respectively (Invitrogen). After immunoreaction of FLAG-
enzymes the membranes were stripped, and the expression of β-actin was determined. 
All detection and quantification reactions were performed using a LI-COR Odyssey 
Infrared Imaging system (LI-COR, Biosciences, Lincoln, NE).  
 
CALCULATION OF ENZYME KINETIC PARAMETERS 
Enzyme kinetics were analysed by non-linear regression using four-parameter logistic 
curve fitting. For statistical comparisons, the ratio t-test in GraphPad Prism 5 software 
was used. Results (mean ± S.D.) were obtained from at least three independent 
experiments. For calculation of Vmax, the expression level of the FLAG-tagged enzyme 
was compared with the expression signal from β-actin as an internal control.  
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MICROSOMAL PREPARATIONS AND ACTIVITY ASSAYS USING 
WILD-TYPE AND LIVER-SPECIFIC 11Β-HSD1 KNOCKOUT LIVER 
MICROSOMES 
Mouse wild-type and liver-specific 11β-HSD1 dificient liver microsomes were prepared 
as previously described (Senesi, Legeza et al. 2010). Thereafter, the quality of 
microsomal preparations was validated by measuring NADPH-Cytochrome c reductase 
activity (Sigma, Saint Louis, MO). To assess 11β-HSD1 reductase activity microsomes 
(0.05 mg/mL) were incubated for 60 min at 37°C in a total volume of 25 μL containing 
TS2 buffer, 500 μM NADPH or 1 mM G6P, 1 μM of 7-oxoLCA or 1 of µM cortisone, and 
vehicle or 5 μM of the 11β-HSD1 inhibitor as indicated. Substrates and inhibitors were 
diluted from 10 mM stock solutions in DMSO or in methanol. The final solvent 
concentration in all reactions was kept below 0.2%. Reactions were started by adding 
microsomes into freshly prepared reaction mixture and stopped by adding 500 µL of 
acetonitrile containing CDCA-d4 and cortisol-d4 at the concentration of 100 nM as 
internal standards for UPLC-MS/MS analysis. Thereafter, the organic phase was 
evaporated to dryness, samples were reconstituted in 50% methanol/water solution and 
injected in the UPLC-MS/MS. 
 
ANIMAL EXPERIMENTATION 
In order to assess the impact of 11β-HSD1 on BA homeostasis and to determine the 
circulating levels of 7-oxoLCA and conjugated metabolites, 16 adult wild-type male 
C57BL/6 mice and 16  liver-specific 11β-HSD1 deficient mice (previously described by 
(Lavery, Zielinska et al. 2012), were fasted overnight and blood collected by intra-
cardiac puncture. Serum was prepared and samples were stored at -80 ºC until further 
processing.  
ANALYSIS OF BILE ACID PROFILES BY UPLC-MS/MS 
Extraction and quantification of BAs were done as previously described, with the 
exception that T-ω-MCA was included in the method (Penno, Arsenijevic et al. 2013). 
The extraction of BAs and glucocorticoids from liver tissue was performed using 100 mg 
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of tissue homogenized in 200 µL 50% methanol. Samples were spiked with 300 µL of 
deuterium labeled BAs (UDCA-d4, CDCA-d4, LCA-d4, G-UDCA-d4, G-CA-d4, CA-d4 
and DCA-d4) at the final concentration of 1000 nM in acetonitrile followed by protein 
precipitation with 1.5 mL of alkaline ice-cold acetonitrile (5% NH4OH). Thereafter, 
samples were shaked continuously for 1 h and centrifugated at 11,000×g for 10 min. 
The supernatant was transferred to a new tube, evaporated and reconstituted in 100 µL 
of 50% methanol and further centrifugated to remove insoluble particles. The method 
was qualified on the basis of extraction efficiency, intra-day accuracy and precision for 
representative BAs including CA, CDCA, DCA. LCA, α-MCA, G-CDCA, G-UDCA, T-CA, 
T-α-MCA. The method presented acceptable extraction efficiency, accuracy and 
precision for the BAs studied (Supplemental Table 1, 2, and 3). 
GENE EXPRESSION 
Total mRNA was extracted from liver tissue using Trizol (Invitrogen, Carlsbad CA) 
according to the manufacturer´s instruction. RNA concentration and purity was 
determined spectrophotometrically (NanoDrop™ 1000 Spectrophotometer, Thermo 
Scientific) by measuring fluorescence at 260 nm, 230 nm and 280 nm. 2 μg of total 
mRNA was reverse transcribed to cDNA using the Superscript III First-Strand Synthesis 
System and oligo dT following the manufacturer´s instruction (Invitrogen). Relative 
quantification of genes involved in BA homeostasis was performed by RT-PCR 
(RotorGene 6000; Corbett) and using SYBR Green (KAPA SYBR® FAST qPCR Kit). 
The relative expression of each gene compared with the internal control cyclophiline 
was determined using the delta-delta-CT method. Primers were either obtained from 
Sigma or synthesized from validated sequences obtained at Primerbank (Wang, 
Spandidos et al. 2012). Quality of primers was evaluated by determination of their 
melting curves. Samples were evaluated in triplicates (supplemental Table 5).  
TRANSIENT TRANSFECTION AND REPORTER ASSAYS 
In FXR transactivation assays, Huh7 cells were seeded at 1 × 105 cells per well in 24-
well plates and transfected using JetPEI (Polyplus) with 375 ng of hOATP1b3 luciferase 
reporter construct (Jung, Podvinec et al. 2002) and 175 ng of plasmids for FXR, RXRα 
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and human 11β-HSD1. To normalize the amount of CMV promoter-containing 
expression constructs, an appropriate amount of the pcDNA3.1 (+) vector (Invitrogen) 
was included in transfection mixtures. To control for variations in transfection efficiency 
125 ng of the phRG-TK Renilla reniformis luciferase reporter plasmid (Promega) was 
cotransfected in each well. Twelve hours after transfection cells were treated with 
vehicle, ligands and inhibitors as indicated. Twenty-four hours after adding the ligands, 
cells were harvested in 1 × Passive Lysis Buffer (Promega), and luciferase activities 
were measured with luminometer (SpectraMax). Relative promoter activities were 
obtained by normalizing firefly luciferase activities to R. reniformis luciferase activities. 
VDR transactivation assays were performed similarly in Caco-2 cells, using a luciferase 
reporter construct based on the human PCFT promoter (Proton-coupled Folate 
Tranporter) (Eloranta, Zaïr et al. 2009). 
STATISTICAL ANALYSIS 
Data are presented as mean ± SD. Statistical significance was assessed by Student´s t 
test. A  p-value ≤ 0.05 was considered to be significant.  
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RESULTS  
COMPARISON OF 11Β-HSD1-MEDIATED 7-OXOLCA OXOREDUCTION 
BY SIX SPECIES 
We have previously shown that human 11β-HSD1 preferentially converts 7-oxoLCA to 
CDCA. Evidence from studies using rat liver microsomes indicated the formation of both 
CDCA and UDCA from 7-oxoLCA. In the present study, we investigated whether these 
differences are due to species-specific differences in the stereoselective product 
formation by 11β-HSD1 or whether additional enzymes might be relevant to 7-oxoLCA 
reduction in rodents. Recombinant 11β-HSD1 from six species were expressed in HEK-
293 cells and the oxoreduction of 7-oxoLCA was determined. We observed that canine 
and hamster 11β-HSD1 presented stereoselectivity similar to that of human 11β-HSD1, 
thus producing higher levels of the 7α-hydroxyl chenodeoxycholic acid (CDCA) and 
minor amounts of the 7β-hydroxyl ursodeoxycholic acid (UDCA). Interestingly, rat and 
mouse 11β-HSD1 reduced 7-oxoLCA to equivalent amounts of CDCA and UDCA 
(Figure 1A). Surprisingly, we did not observe 7-oxoLCA oxoreduction using HEK-293 
cell lysates expressing recombinant guinea-pig 11β-HSD1 nor when using guinea-pig 
liver microsomes (Figure 1A and 1B), in spite of the fact that cortisone was efficiently 
reduced by recombinant guinea-pig 11β-HSD1 with a Vmax of 8 nmol×h-1×mg-1, similar 
to an earlier report (Arampatzis, Kadereit et al. 2005)  (Figure 1 C, Table 1). On the 
other hand, 11β-HSD1 from human, mouse, rat, hamster and dog efficiently converted 
7-oxoLCA (Table 1). 
PROFILING OF CIRCULATING BILE ACIDS IN VARIOUS SPECIES 
Owing to the fact that 7-oxoLCA oxoreduction activity was absent in guinea-pig liver 
microsomes and in lysates of HEK-293 expressing recombinant guinea-pig 11β-HSD1, 
we hypothesized that 7-oxoLCA and its conjugated metabolites would accumulate in the 
serum of guinea-pigs. To assess this hypothesis, we compared BA profiles in serum of 
various species including humans, mice (balb/c and C57bL/6), rats (Han Wistar and 
Sprague-Dawley), canine (Canis familiaris, beagle bred), guinea-pig (dunkin-hartley) 
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and hamster (golden syrian). As expected, we observed elevated levels of 7-oxoLCA 
and its glycine conjugate in serum of guinea-pigs in contrast to other species studied 
(Table 2), whereas T-7-oxoLCA levels were negligible. In addition, the comparison of BA 
profiles among species revealed species-dependent differences with regard to 
circulating BAs composition (supplemental Table 4)   
RELATIVE CONTRIBUTION OF 11Β-HSD1 TO THE OXOREDUCTION 
OF 7-OXOLCA.   
In order to clarify whether 7-oxoLCA oxoreduction is mainly due to 11β-HSD1 activity or 
whether other enzymes may be also relevant, we performed experiments with liver 
microsomes derived from liver-specific 11β-HSD1 deficient mice (Lavery, Zielinska et al. 
2012). We supplied NADPH or glucose-6-phosphate (G6P) in order to distinguish 
between NADPH-dependent enzymes that are oriented to the cytosol (e.g. cytochrome 
P450 and aldoketoreductases) and enzymes that are facing the endoplasmic reticulum 
(ER), such as 11β-HSD1. In the ER lumen, NADPH is regenerated by H6PDH, which is 
primarily dependent on G6P under physiological conditions (Clarke and Mason 2003). 
After 60 min of incubation with G6P approximately 60% of initially supplied 7-oxoLCA 
was converted to approximately 40% CDCA and 20% UDCA. The reaction was inhibited 
by the 11β-HSD1 specific inhibitor T0504 (also known as Merck-544). When NAPDH 
was supplied, we observed only traces formation of CDCA and UDCA, which were 
abolished by T0504, suggesting that either a small amount of NAPDH can penetrate 
into the microsomes or, more likely, that a small fraction of microsomes have inverted 
orientation. Importantly, in identical experiments using liver-specific 11β-HSD1 deficient 
liver microsomes we did not detect 7-oxoLCA reduction, regardless of whether G6P or 
NADPH was supplied to the reaction mixture (Figure 2). On the other hand, wild-type 
and liver-specific 11β-HSD1 deficient liver microsomes showed comparable cytochrome 
c reductase activity (data not shown).   
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IMPACT OF LIVER-SPECIFIC 11Β-HSD1 DISRUPTION ON 
CIRCULATING LEVELS OF 7-OXOLCA AND ITS CONJUGATED 
FORMS  
We hypothesized that in a scenario of hepatic 11β-HSD1 disruption, circulating levels of 
7-oxoLCA and its conjugated metabolites would elevate as observed in guinea-pigs, 
who are devoid of 7-oxoLCA oxoreductase activity. Therefore, we assessed the 
concentrations of 7-oxoLCA and its tauro- and glyco-conjugates in serum and liver 
tissue of liver-specific 11β-HSD1 deficient mice (Figure 3). As expected, circulating and 
hepatic 7-oxoLCA, T-7-oxoLCA and G-7-oxoLCA levels were 18, 47 and 7-fold elevated 
in serum of liver-specific 11β-HSD1 deficient compared with wild-type mice, 
respectively. Similarly, in liver, 7-oxoLCA and T-7-oxoLCA were 2- and 6-fold elevated, 
whereas G-7-oxoLCA levels were unchanged (Figure 3).  
BAS PROFILE IN SERUM AND LIVER OF LIVER-SPECIFIC 11Β-HSD1 
DEFICIENT MICE 
The glucocorticoid receptor (GR) is an important modulator of BA homeostasis 
(Eloranta, Jung et al. 2006; Rose, Díaz et al. 2011; Lu, Zhang et al. 2012). In order to 
assess the impact of liver-specific 11β-HSD1 disruption on BA homeostasis, we 
assessed the circulating and hepatic BA levels in liver-specific 11β-HSD1 deficient mice 
by UPLC-MS/MS (Penno, Arsenijevic et al. 2013). As expected, liver-specific 11β-HSD1 
disruption caused disturbances in BA homeostasis. Circulating unconjugated BAs such 
as CA, CDCA, 7-oxoDCA and α-MCA were 4- to 16-fold significantly elevated, whereas 
DCA, HDCA, UDCA, β-MCA and ω-MCA trended to increase, but did not reach 
statistical significance. Circulating taurine-conjugated species trended to increase up to 
8-fold (Table 3); however, statistical significance was not reached for any taurine-BA 
studied. Intrahepatic BA profiling has revealed a significant increase of several 
unconjugated BAs in liver-specific 11β-HSD1 deficient compared with wild-type mice 
(Table 4). BA metabolites such as CA, 7-oxoDCA, HDCA, UDCA, α-MCA, and ω-MCA 
were up to 8-fold significantly elevated. On the other hand, several taurine- and glycine-
LACK OF 7-OXOLCA REDUCTION BY 11B-HSD1 LEADS TO ITS ACCUMULATION: A 
POTENTIAL BIOMARKER OF IMPAIRED GLUCOCORTICOID ACTIVATION. 
 
64 
 
conjugated BA such as T-DCA, T-LCA, T-β-MCA, T-ω-MCA, G-CA, G-DCA, G-LCA and 
G-UDCA levels trended to decrease in liver from liver-specific 11β-HSD1 deficient mice 
when compared with wild-type controls, whereas T-UDCA levels reached statistical 
significance. Of note, T-α-MCA levels were 3-fold significantly increased in liver from 
liver-specific 11β-HSD1 deficient mice. Nevertheless, total taurine- and glycine-
conjugated BA levels suggest a rather decrease of their concentrations upon liver-
specific 11β-HSD1 disruption in mice (Table 4). 
GENE EXPRESSION 
To understand the changes in BA homeostasis observed in liver-specific 11β-HSD1 
deficient mice, we analysed the expression of genes involved in BAs homeostasis. We 
observed reduced expression levels of VLCS and VLCSH2, enzymes which possess 
BA coenzyme A synthetase activity. In addition, we found that the expression levels of 
CYP7A1 and OATP4 were reduced, while SHP-1 was up-regulated.  All the other genes 
studied presented unchanged expression levels compared with wild-type mice (Figure 
4).     
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DISCUSSION 
Biomarkers for impaired 11β-HSD1 activity are of great interest for clinical researchers 
as well as for pharmaceutical industry in order to assess the in vivo efficacy of 
therapeutic inhibitors. Despite the fact that their efficiency can also be assessed through 
traditional and indirect clinical markers such as fasting plasma glucose and lipid profiles, 
biomarkers to assess direct 11β-HSD1 inhibition in preclinical and clinical trials are still 
unavailable. In this regard, although it has been demonstrated that 11β-HSD1 deficient  
mice have slightly elevated plasma levels of corticosterone and adrenocorticotropic 
hormone (ACTH), strain-dependent differences have been a major problem (Harris, 
Kotelevtsev et al. 2001; Carter, Paterson et al. 2009). Interestingly, neither 11β-HSD1 
full knockout, liver-specific 11β-HSD1 knockout, H6PDH knockout nor 11β-
HSD1/H6PDH double knockout developed on a C57BL/6J/129SvJ background 
presented elevated levels of circulating corticosterone when compared with wild-type 
mice (Semjonous, Sherlock et al. 2011; Abrahams, Semjonous et al. 2012; Lavery, 
Zielinska et al. 2012). Therefore, it is reasonable to assume that its levels are unlikely to 
be affected upon therapeutic intervention, thus excluding the applicability of 
glucocorticoids levels as a biomarker of 11β-HSD1 inhibition. Likewise, urinary levels of 
11-dehydrocorticosterone (11-DHC) are also of limited application owing to the fact that 
in heterozygous 11β-HSD1 knockout, H6PDH knockout, 11β-HSD1/H6PDH double 
knockout as well as in liver-specific 11β-HSD1 knockout mice levels are essentially 
similar to wild-type controls (Abrahams, Semjonous et al. 2012; Lavery, Zielinska et al. 
2012). Therefore, the loss of one HSD11B1 allele, a scenario similar to 50% enzymatic 
inhibition, is insufficient to elicit a significant change in urinary 11-DHC metabolites 
(Abrahams, Semjonous et al. 2012). Recently, we have identified a novel substrate of 
human 11β-HSD1, the secondary bile acid 7-oxoLCA, which is efficiently metabolized to 
the 7α-hydroxyl CDCA and to a lesser extent to 7β-hydroxyl UDCA in vitro (Odermatt, 
Da Cunha et al. 2011). 11β-HSD1-dependent metabolism of 7-oxoLCA was irreversible, 
unlike the metabolism of glucocorticoids, and its taurine and glycine conjugates were 
also efficiently metabolized (Odermatt, Da Cunha et al. 2011). The stereo specificity of 
the reaction is opposite to that observed for other alternative 11β-HSD1 substrates such 
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7-oxodehydroepiandrosterone, 7-oxopregnenolone and 7-ketocholesterol which are 
preferentially converted to their 7β-hydroxyl metabolites (Schweizer, Zürcher et al. 
2004; Nashev, Chandsawangbhuwana et al. 2007). Using recombinant enzymes 
expressed in HEK-293 cells we found remarkably species differences. Surprisingly, 
rodents produced equivalent amounts of 7α- and 7β- isomers, whereas hamster and 
canine 11β-HSD1 are catalytically similar to human 11β-HSD1, thus becoming the 
preferred animal models to extrapolate the potential physiological and toxicological 
effects of 11β-HSD1 inhibition and 7-oxoLCA accumulation to humans (Figure 1 A). It 
has been suggested that canine and hamster might have limited utility for the 
assessment of the potential toxicological consequences of 11β-HSD1 inhibition with 
regard to the accumulation of the toxic oxysterol 7-ketocholesterol, owing to their low 
catalytic efficiency and different stereospecificity to that of humans (Arampatzis, 
Kadereit et al. 2005). Overall, these results highlight that the selection of the most 
suitable animal model to assess safety of 11β-HSD1 inhibitors is complex and must 
take into account the large species-dependent differences of endogenous and 
xenobiotics metabolism (Odermatt and Nashev 2010).  In this study, human, canine and 
rat 11β-HSD1 displayed the highest catalytic efficiency of 7-oxoLCA oxoreduction while 
mouse and hamster enzymes showed lower activities (Table 1). Surprisingly, guinea-pig 
11β-HSD1 is unable to reduce 7-oxoLCA in cell lysates and guinea-pig liver 
microsomes do not convert 7-oxoLCA, hence likely to be the underlying cause of 7-
oxoLCA and G-7-oxoLCA accumulation in the circulation of fasted guinea-pigs in 
comparison to other species (Table 2). This finding is also in line with an earlier study 
pointing out 7-oxoLCA as a primary BA in guinea-pigs, accounting for 30% of 
gallbladder BAs (Tint, Xu et al. 1990). Owing to the fact that 7-oxoLCA and its glycine-
conjugate accumulated in the circulation of guinea-pigs due to an apparent impaired 7-
oxoLCA reductase activity and because 11β-HSD1 seems to be the exclusive 
microsomal enzyme responsible for its reduction, we speculated that 7-oxoLCA and 
conjugates would also accumulate in liver-specific 11β-HSD1 deficient mice. We have 
observed a trend increase of hepatic and a significant elevation of circulating 7-oxoLCA 
(2- and 18-fold, respectively). Importantly, a significant increase of hepatic and 
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circulating T-7-oxoLCA (6- and 47-fold, respectively) was observed, suggesting that 
taurine conjugation of 7-oxoLCA is the main route for its elimination in mice. Based on 
these findings, we hypothesized that 7-oxoLCA and particularly T-7-oxoLCA 
accumulation may serve as a superior readout of 11β-HSD1 inhibition in mice. In 
addition, 7-oxoLCA is independent of the HPA axis feedback regulation, it is not 
involved in adaptive metabolic changes, it lacks overt toxicity, yet it has been shown to 
reduce the biliary lithogenic index (Salen, Verga et al. 1982), and as revealed in the 
present study, it is an exclusive substrate of 11β-HSD1. Moreover, 7-oxoLCA  is not a 
ligand for the VDR (Makishima, Lu et al. 2002) and does not activate FXR to the same 
extent as CDCA and UDCA (Supplemental Figure 1), thus it unlikely influences the 
activity of these nuclear receptors. Due to the fact that in humans circulating glycine-
conjugated BAs are more abundant than taurine-conjugated metabolites, in this species 
G-7-oxoLCA levels might correlate with 11β-HSD1 inhibition (Supplemental Table 4) 
(Garcia-Canaveras, Donato et al. 2012). In guinea-pigs, like in humans, circulating 
glycine-conjugated BAs are more abundant than taurine-conjugated metabolites and 
only traces of T-7-oxoLCA were detected in this species, whereas the concentration of 
G-7-oxoLCA was approximately 13 µM (Table 2). These findings are in line with 
observation of other investigators (Guertin, Loranger et al. 1995).  Similar to humans 
and guinea-pigs, glycine conjugation seems to prevail in hamsters (Supplemental Table 
4), as also observed by others (Cowles, Lee et al. 2002). Conversely, in rodents and 
canine taurine-conjugation prevails and only minor amounts of glycine-conjugated BAs 
were found (Supplemental Table 4), results which are in line with other investigators 
(Washizu 1991; Garcia-Canaveras, Donato et al. 2012). Nevertheless, the applicability 
of 7-oxoLCA and T-7-oxoLCA as potential biomarkers has to the further investigated in 
vivo with specific 11β-HSD1 inhibitors in cortisone reductase deficiency patients.  
Owing to the fact that glucocorticoids are modulators of BA homeostasis, we assessed 
the influence of liver-specific 11β-HSD1 disruption on BAs handling.  In order to dissect 
the effects of glucocorticoids on BA homeostasis, administration of synthetic 
glucocorticoids (e.g., dexamethasone, prednisone, budesonide) in rodents is a common 
approach; however, the fact that they may modulate the activity of other nuclear 
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receptors, including CAR and PXR (Pascussi, Drocourt et al. 2000; Pascussi, Gerbal-
Chaloin et al. 2000), and that dose selection, treatment duration, animal strains/species 
and compound specific properties make it particularly challenging to compare data from 
different studies (Cheng, Buckley et al. 2007; Lu, Zhang et al. 2012; Rosales, Romero 
et al.). In order to overcome those obstacles, we hypothesized that liver-specific 11β-
HSD1 deficient mice would represent a more physiologically relevant model to study the 
effects of glucocorticoids and GR on BAs since these mice are still able to regenerate 
35-40% of glucocorticoids, present no major gene expression changes in the 
gluconeogenic pathway, and the levels of circulating  and hepatic glucocorticoids were 
unaltered (Supplemental Figure 2) (Lavery, Zielinska et al. 2012). Given that 11β-HSD1 
immunostaining in hepatocytes is prominent at adjacent sites of the central vein and 
decreases toward the portal vein, we assumed that a heterogeneous intrahepatic 
distribution of active glucocorticoids in liver-specific 11β-HSD1 deficient mice may elicit 
the observation of glucocorticoids and GR-dependent changes on BAs homeostasis at 
physiological concentrations (Ricketts, Verhaeg et al. 1998; Brereton, van Driel et al. 
2001).  In fact, the profile of BAs has revealed disturbances in BA homeostasis caused 
by liver-specific 11β-HSD1 disruption, which included a significant accumulation of 
several unconjugated BAs in liver, while conjugated BA levels were rather decreased, 
suggesting a reduction of the BA conjugating machinery, an observation which is in line 
with the decreased expression levels of very long-chain coenzyme A synthetase (VLCS) 
and very long-chain acyl-coenzyme A synthetase homolog 2 (VLCSH2) in liver of liver-
specific 11β-HSD1 deficient compared to wild-type mice. Gene expression profiles also 
revealed reduced expression levels of CYP7A1, an effect likely to be mediated by the 
small heterodimer partner (SHP-1), suggesting an enhanced FXR transcriptional 
activity. SHP-1 is a known common negative regulator of CYP7A1, and orchestrates a 
compensatory genetic program to counteract intrahepatic BA accumulation in 
cholestatic situations by interfering with the activity of liver X receptor-α (LXR-α) and 
liver receptor homologue 1 (LRH-1) (Goodwin, Jones et al. 2000; Zhang and Chiang 
2001; Brendel, Schoonjans et al. 2002; Båvner, Sanyal et al. 2005). Surprisingly, BACS 
is also a FXR positively regulated gene; however, the expression levels of two enzymes 
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presenting BA-CoA synthase activity were found to be reduced (Pircher, Kitto et al. 
2003). The reasons for these are unclear; it might be a direct and FXR-independent 
effect of the GR since in silico analysis of 6 KB of the promoter/enhancer sequence of 
VLCS and VLCSH2 indicated the existence of a putative DNA binding site of GR 
(Supplemental Figure 3). Lu et. al. showed in a recent study that the direct interaction 
between the GR and the FXR reduced FXR transcriptional activity through the 
recruitment of CtBP co-repressor complexes, consequently stimulated BA synthesis in 
mice and promote BA accumulation in the liver and serum upon dexamethasone (DEX) 
treatment in mice (Lu, Zhang et al. 2012). Interestingly, DEX effects on BA 
accumulation were blunted in FXR-null mice, suggesting that GR-mediated FXR 
reduced transcriptional activity is the main pathway leading to the disturbed BAs 
homeostasis seen in DEX-treated mice. Nevertheless, DEX-mediated BSEP gene up-
regulation was not blunted in FXR-null mice, which suggests the existence of GC-
mediated and FXR-independent gene expression changes (Lu, Zhang et al. 2012). 
Therefore, it is plausible that similar mechanisms are involved in the down-regulation of 
VLCS and VLCSH2 genes down-regulation in liver-specific 11β-HSD1 deficient mice.  
We have not observed changes in the expression level of the Na+-taurocholate 
transporting polypetide (NTCP) (Rose, Díaz et al. 2011; Rosales, Romero et al. 2013), 
the chief transporter of conjugated BAs on the basolateral membrane, in spite the fact 
that NTCP transcription levels are also modulated by FXR and glucocorticoids (Denson, 
Sturm et al. 2001; Eloranta, Jung et al. 2006; Rose, Díaz et al. 2011).  Supporting our 
findings is the fact that liver-specific 11β-HSD1 deficient mice presented only a trend to 
accumulate taurine-BAs in the circulation. On the other hand, OATP4 (also known as 
OATP1b2) expression was significantly reduced. It has been shown that OATP4 
mediates the hepatic uptake of unconjugated BAs (Csanaky, Lu et al. 2011).  It remains 
to be further investigated whether the reduced expression of OATP4 in the liver of liver-
specific 11β-HSD1 deficient mice represents an alternative mechanism to prevent a 
further uptake of unconjugated BAs into hepatocytes and thus responsible for the 
accumulation of unconjugated BAs in serum from liver-specific 11β-HSD1 mice. In silico 
analysis of the promoter/enhancer sequence of OATP4 revealed putative GR binding 
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sites; hence glucocorticoids may modulate its expression as well. In contrast to other 
studies using pharmacological intervention with synthetic glucocorticoids to understand 
the role of glucocorticoids and GR in BAs homeostasis, we assumed that liver-specific 
11β-HSD1 deficient mice represents a more physiological relevant model, given the lack 
of major metabolic abnormalities in these mice (Cheng, Buckley et al. 2007; Lavery, 
Zielinska et al. 2012; Rosales, Romero et al.). Moreover, the impact of liver-specific 
11β-HSD1 disruption on classic gluconeogenic target genes, including genes such as 
phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatese catalytic subunit 
(G6Pase), glucokinase, and peroxisome proliferator-activated receptor gamma 
coactivator 1α expression levels, was minimal (Lavery, Zielinska et al. 2012). In this 
context, our results might shed light on the initial mechanism involved in the 
dysregulation of GR-mediated BAs homeostasis, given that the distribution of 
glucocorticoids, rather than its systemic concentrations across the liver of liver-specific 
11β-HSD1 deficient mice might explain the altered BA homeostasis. 
CONCLUSIONS 
In this study, we provide further evidences for an exclusive role of 11β-HSD1 in the 
metabolism of 7-oxoLCA. 7-oxoLCA and particularly its taurine-conjugate were 
markedly elevated in the serum of liver-specific 11β-HSD1 deficient mice and therefore 
may be potentially used as a biomarker to identify impaired 11β-HSD1 activity in 
clinically relevant situation and to assess the efficacy of 11β-HSD1 inhibitors. Moreover, 
we observed that liver-specific 11β-HSD1 disruption disturbs BA homeostasis and 
promoted intrahepatic accumulation of BAs, particularly by reducing VLCS and VLCSH2 
gene expression. Furthermore, the expression levels of the BA transport OATP4 were 
reduced. This might represent the initial mechanism of GR-modulation of BAs 
homeostasis.  The potential physiological consequences of a disturbed BA homeostasis 
upon a therapeutic intervention with 11β-HSD1 inhibitors and the possible combination 
with known cholestatic drugs warrant further investigation. 
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FIGURES  
 
 
 
Figure 1. Enzymatic activity of recombinant 11β-HSD1 from various species was 
determined in lysates of transfected HEK-293 cells as described in “Materials and 
Methods.” A, Stereoselectivity of 7-oxoLCA (2 µM) oxoreduction to CDCA (black bars) 
and UDCA (white bars) formed by 11β-HSD1 from various species after 10 min 
incubation at 37ºC. B, Guinea-pig liver microsomes were incubated for 40 min with 7-
oxoLCA (1 μM) and glucose-6-phosphate (1 mM). BAs were extracted and quantitated 
by UPLC-MS/MS. Unconverted 7-oxoLCA is represented by black bars. Data (n=3) 
represent mean ± SD. C, Oxoreduction of cortisone by guinea-pig liver microsomes. D, 
Western blotting against 11β-HSD1 in guinea-pig (GPLm) and mouse liver microsomes 
(MLm)
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Figure 2. Wild-type or liver-specific 11β-HSD1 knockout (LKO) liver microsomes were 
incubated for 60 min with 7-oxoLCA (1 µM), hexose-6-phosphate (1 mM G6P) or 
NAPDH and 11β-HSD1 inhibitor T0504 (5 µM) as indicated. 7-oxoLCA is represented 
by white bars, CDCA and UDCA are represented by black and hatched bars, 
respectively. Data (n=3) represent mean ± SD. Reactions were terminated with 
acetonitrile extracted and measured by UPLC-MS/MS.
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Figure 3. Circulating and intrahepatic concentrations of 7-oxoLCA, taurine-7-oxoLCA 
and glycine-7-oxoLCA of wild-type (WT) and liver-specific 11β-HSD1 deficient (LKO) 
mice. Data (n=16) represent mean ± SD. Statistics* for p ≤ 0.05. 
.
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Figure 4. Gene expression profiles in liver of wild-type and liver-specific 11β-HSD1 
deficient (LKO) mice: BA synthesis, basolateral uptake, BA efflux, BA conjugation, 
canaliculi efflux and transcription factors involved in BA homeostasis as indicated. Data 
(n=16) represent mean ± SD. Statistics: * for p ≤ 0.05. 
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Supplemental Figure 1. FXR and VDR transactivation assays. Right panel: Huh7 cells 
were transfected with hOATP1b3 luciferase reporter construct together with FXR, RXRα 
and human 11β-HSD1 expression constructs. Left panel: Caco-2 cells were transfected 
with human PCFT promoter together with FXR, RXR expression constructs. Twelve 
hours after transfection, cells were treated with vehicle, ligands and 11β-HSD1 inhibitor 
(T0504) as indicated. Twenty-four hours after adding the ligands, cells were harvested 
and luciferase activity was measured. 
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Supplemental Figure 2. A, Intrahepatic levels of corticosterone (B) and 11-
dehydrocorticosterone (A) in wild-type (WT) and liver-specific 11β-HSD1 deficient (LKO) 
mice. B, B/A ratios in liver of wild-type (WT) and liver-specific 11β-HSD1 knockout 
(LKO). Data (n=16) represent mean ± SD. 
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Supplemental Figure 3. In silico analysis of putative GR responsive elements in 6 KB 
of promoter/enhancer of mouse VLCS, VLCSH2 and OATP4 genes. Six KB of 
promoter/enhancer sequences of mouse VLCS and VLCSH2 were assessed from the 
genomic DNA database (www.ensembl.org). The DNA sequences were analysed by 
Alibaba2.1 (http://www.gene-regulation.com/pub/programs/alibaba2/). 
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TABLES  
 
Table 1 Comparison of enzyme kinetic comparison of the oxoreduction of 7-oxoLCA and cortisone by recombinant 11β-
HSD1 from six species. 
 Oxoreduction of 7-oxoLCA  Oxoreduction of cortisone 
Species Km [µM] Vmax [nmol×h-1×mg-1] Vmax [nmol×h-1×mg-1] 
Canine 1.9 ± 0.4 8.8 ± 1.0 2.2 
Guinea-pig - - 8.0 
Hamster 1.9 ± 0.2 23.9 ± 1.1 10.4 
Human 1.2 ± 0.1 4.0 ± 0.2 3.9 
Mouse 2.6 ± 0.4 27.1 ± 2.0 12.9 
Rat 2.3 ± 0.5 11.6 ± 1.2 6.0 
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Table 2 Concentrations of 7-oxoLCA and its conjugates in serum from several species.  
 
 
 Dog Guinea-pig Hamster Human Balb/c*
2 C57BL/6*2 HW*3 SD*3 
7-oxoLCA 41 ± 83 13593 ± 5482 11 ± 9 3 ± 1 20 ± 12 6 ± 4 4 ± 5 22 ± 28 
T-7-oxoLCA 9 ± 11 3 ± 2 3 ± 1 1 ± 0.1 8 ± 2 32 ± 14 2 ± 0.2 4 ± 1 
G-7-oxoLCA 1 ± 0.2 13005 ± 21535 1 ± 1 1 ± 0.1 5 ± 3 N.D. N.D. 1 ± 2 
 
The results are expressed in nM as mean ± standard deviation (n=8). Underlined values represent below lower limit of 
quantification. *2 Mouse (Balb/c, C57BL/6); *3 Rats (Sprague-Dawley (SD), Han Wistar (HW)); N.D.: not detected. 
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Table 3 Comparison of bile acid profiles in serum from wild-type and liver-specific 11β-
HSD1 deficient mice. 
 
WT LKO Fold change 
CA 528 ± 359 3232 ± 4704* 6 
CDCA 20 ± 21 71 ± 86* 4 
DCA 186 ± 178 425 ± 607 2 
7-oxoDCA 239 ± 302 2846 ± 3688* 12 
HDCA 36 ± 31 64 ± 73 2 
LCA N.D. N.D.  
α-MCA 67 ± 71 1089 ± 1602* 16 
β-MCA 904 ± 597 1293 ± 1866 1 
ω-MCA 888 ± 614 1842 ± 2133 2 
UDCA 92 ± 66 145 ± 188 2 
Sub-total 2960  11006 4 
    
T-CA 5255 ± 15320 17334 ± 26835 3 
T-CDCA 247 ± 709 859 ± 1340 3 
T-DCA 383 ± 825 1302 ± 2568 3 
T-LCA 2 ± 4 19 ± 47 8 
T-α-MCA 2365 ± 8363 8648 ± 15518 4 
T-β-MCA 2861 ± 5229 7579 ± 16824 3 
T-ω-MCA 1463 ± 2761 9342 ± 18918 6 
T-UDCA 130 ± 262 414 ± 1016 3 
Sub-total 12707 45497 4 
    
G-CA 19 ± 40 104 ± 981 5 
G-CDCA N.D. N.D.  
G-DCA N.D. N.D.  
G-LCA N.D. N.D.  
G-UDCA N.D. N.D.  
    
Total BAs 15686 56607 4 
 
The results are expressed in nM as mean ± standard deviation (n=16). N.D.: not 
detected. Statistics: * for p ≤ 0.05., WT, wild-type and LKO, liver-specific 11β-HSD1 
deficient mice. 
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Table 4 Comparison of bile acid profiles in liver of wild-type and liver-specific 11β-HSD1 
deficient mice. 
WT LKO Fold change 
CA 1002 ± 1250 2794 ± 2542* 3 
CDCA 9 ± 8 13 ± 12 2 
DCA 33 ± 46 48 ± 64 1 
7-oxoDCA 492 ± 939 3239 ± 3358* 7 
HDCA 18 ± 18 41 ± 47* 2 
LCA N.D.  N.D.  
α-MCA 178 ± 188 1342 ± 1498* 8 
β-MCA 1346 ± 1276 1211 ± 1023 1 
ω-MCA 634 ± 734 1589 ± 1526* 3 
UDCA 51 ± 53 124 ± 105* 2 
Sub Total 3764  10401 3 
    
T-CA 29827 ± 32975 33235 ± 23505 1 
T-CDCA 1177 ± 1060 1333 ± 1071 1 
T-DCA 1921 ± 3756 1184 ± 1469 0.6 
T-LCA 26 ± 26 20 ± 17 0.8 
T-α-MCA 2762 ± 3178 7324 ± 7928* 3 
T-β-MCA 12584 ± 10870 7652 ± 5608 0.6 
T-ω-MCA 16473 ± 12523 14000 ± 9936 0.8 
T-UDCA 1377 ± 1060 472 ± 1005* 0.3 
Sub Total 66147 65224 1 
    
G-CA 116  ± 155 110  ± 140 0.9 
G-CDCA 7 ± 3 7  ± 3 1.0 
G-DCA 10 ± 9 6 ± 3 0.6 
G-LCA 2 ± 3 1 ± 0.2 0.3 
G-UDCA 7 ± 7 3 ± 4 0.5 
Sub Total 142   128   0.9 
    
Total 70053 75750 1 
 
The results are expressed in fmol/mg of tissue as mean ± standard deviation (n=16). 
N.D.: not detected. Statistics: * for p ≤ 0.05. WT, wild-type and LKO, liver-specific 11β-
HSD1 deficient mice. 
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Supplemental Table 1: Extraction efficiency of selected BAs in liver tissue. 
 
 
 
 
 
 
 
 
 
Supplemental Table 2: Precision of selected BAs in liver tissue. 
 
 Precision (CV%) 
Bile acid Endogenous QC low QC middle QC high 
CA 9.7 7.6 5.2 5.2 
CDCA 8.7 9.0 11.1 12.3 
DCA 16.2 14.0 6.3 10.0 
LCA n.d. 15.4 13.6 7.7 
α-MCA 12.0 8.3 7.0 5.0 
G-CDCA 11.5 12.6 7.1 14.0 
G-UDCA 14.9 13.1 8.1 6.4 
T-CA 10.2 14.4 11.3 11.7 
 
Supplemental Table 3: Accuracy of selected BAs in liver tissue. 
 
 Accuracy (%) 
Bile acid QC low QC middle QC high 
CA 91 96 93 
CDCA 95 111 106 
DCA 101 106 114 
LCA 105 104 109 
α-MCA 93 95 90 
G-CDCA 88 94 90 
G-UDCA 103 95 95 
T-CA 95 97 98 
Bile acid Extraction Efficiency (%) 
CA 95 ± 2  
α-MCA 99 ± 1  
G-CDCA 92 ± 1  
T-CA 92 ± 1  
T-α-MCA 92 ± 1  
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Supplemental Table 4 Comparison of bile acid profiles among various species. 
 
 
The results are expressed in nM as mean ± standard deviation (n=8). N.D.: not detected. Underlined values represent below 
lower limit of quantification. 
Canine  Guinea-pig Hamster Human Balb/c C57bL/6 Han Wistar Sprague-Dawley 
CA 701 ± 892 2286 ± 745 2480 ±  956 20 ± 10 57 ± 101 422 ± 387 593 ± 747 2896 ± 1982 
CDCA 196 ± 264 36548 ± 11560 642 ± 420 67 ± 59 39 ± 16 58 ± 39 210 ± 270 706 ± 582 
DCA 193 ± 281 618 ± 317 833 ± 459 138 ± 55 68 ± 34 590 ± 273 174 ± 82 1236 ± 1180 
7-oxoDCA 36 ± 50 45 ± 46 54 ± 21 3 ± 1 3 ± 12 14 ± 21 1 ± 1 85 ± 69 
HDCA N.D. 581 ± 297 17 ± 15 5 ± 4 19 ± 12 28 ± 15 626 ± 374 1743 ± 1125 
LCA 29 ± 36 1443 ± 762 107 ± 108 15 ± 7 1 ± 1.2 8 ± 4 5 ± 5 24 ± 24 
α-MCA N.D. 184 ± 126 N.D.  7 ± 3 6 ± 13.5 71 ± 106 70 ± 101 56 ± 41 
β-MCA N.D. 186 ± 161 N.D. N.D. 63 ± 76 210 ± 229 164 ± 170 367 ± 227 
ω-MCA 2 ± 4 104 ± 133 6 ± 6 4 ± 3 51 ± 43 133 ± 145 89 ± 90 454 ± 209 
UDCA 145 ± 180 6662 ± 3290 49 ± 31 32 ± 19 11 ± 9 83 ± 61 57 ± 60 206 ± 164 
T-CA 251 ± 300 18 ± 14 75 ± 28 24 ± 27 143 ± 75 197 ± 47 226 ± 57 723 ± 454 
T-CDCA 3 ± 4 41 ± 24 2 ± 0.5 97 ± 67 5 ± 1.5 24 ± 16 15 ± 4 19 ± 11 
T-DCA 235 ± 331 41 ± 51 57 ± 24 35 ± 35 166 ± 136 105 ± 66 N.D. 521 ± 201 
T-LCA 51 ± 83 14 ± 9.5 23 ± 6 2 ± 2 N.D. 3 ± 3 6 ± 5 4 ± 5 
T-α-MCA 24 ± 25 5 ± 3.6 N.D. 4 ± 5 30 ± 14 206 ± 41 179 ± 36 408 ± 238 
T-β-MCA 5 ± 6 2 ± 1.8 N.D. 5 ± 7 107 ± 33 182 ± 57 166 ± 47 561 ± 322 
T-UDCA 12 ± 12 5 ± 2.7 1 ± 0.3 5 ± 3 25 ± 12 19 ± 9 4 ± 0.7 4 ± 2.5 
G-CA N.D. 484 ± 326 367 ± 207 162 ± 106 N.D. 87 ± 97 82 ± 87 3 ± 2 
G-CDCA 1 ± 0.5 11688 ± 11037 217 ± 159 1052 ± 584 7 ± 4 1 ± 0.2 4 ± 1.2 66 ± 61 
G-DCA 1 ± 1.9 102 ± 101 219 ± 138 341 ± 291 N.D. 7 ± 4 7 ± 4.2 N.D. 
G-LCA N.D. 297 ± 135 110 ± 62 15 ± 14 N.D. N.D. N.D. 7 ± 9 
G-UDCA N.D. 1045 ± 605 N.D. 144 ± 101 1 ± 0.8 N.D. N.D. 4 ± 5 
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Supplemental Table 5: Primers used for gene expression studies. 
 
 
Gene Forward  Reverse Provider 
Abcb11 ATTAACCTTGGTGATTCTCG ATACCTTTCCACCTCCTTATTC Sigma 
Abcb1a AGGACAAAAGAAGGAACTTG GATAAGGAGAAAAGCTGCAC Sigma 
Abcb1b CTGTTGGCGTATTTGGGATGT CAGCATCAAGAGGGGAAGTAATG primerbank 
Abcc2 CGTATATAAGAAGGCACTAACC CAATCTGTAAAACACTGGACC Sigma 
Abcc3 CACTTTGCTAATCCAGTACG GATCCAAGATTTTACCCTCTG Sigma 
Abcc4 AAACAAAGTCATCCTGTTCG CAGAAAGTTCTTGATCCTCC Sigma 
Baat GGAAACCTGTTAGTTCTCAGGC GTGGACCCCCATATAGTCTCC primerbank 
CYP7A1 CTTGAGGATGGTTCCTATAAC TTAAAAGTCAAAGGGTCTGG Sigma 
CYP8B1 AAGAAGTCGTTCACTTTCAC ACATAATCCTCCTGTACCAC Sigma 
Cyp27a1 AAAGCTGTGATTAAGGAGAC CAAACTGTGTATTCTTGGGG Sigma 
HNF4a GTGGCGAGTCCTTATGACACG GCTGTTGGATGAATTGAGGTTGG primerbank 
Nr0b2 CGATCCTCTTCAACCCAG GAGATCTACCAGAAGGGTG Sigma 
Osta TTTTCTCCATCTTGGCTAAC AGTTCATCACTTGAGACCTG Sigma 
Ostb TGGCAAACAGAAATCGAAAG GCAGAAAGACAAGTGATGAG Sigma 
Slc10a1 CACTGTTCTTCTTTCCTCTC TTTTGTTTGGTCCTTCTGAG Sigma 
Slc27a2 TCCTCCAAGATGTGCGGTACT TAGGTGAGCGTCTCGTCTCG primerbank 
Slc27a5 CTACGCTGGCTGCATATAGATG CCACAAAGGTCTCTGGAGGAT primerbank 
Slco1a1 ACAGATTCAGGCACATTTAC GATTAGAATGAAGACTGCGG Sigma 
Slco1a4 GCTTTTCCAAGATCAAGGCATTT CGTGGGGATACCGAATTGTCT primerbank 
Slco1b2 CAACCTGACTGGTTTTCTATG AAGTGAAGGATCCAATGAAG Sigma 
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6 CONCLUSIONS AND OUTLOOK  
This PhD thesis aimed at understanding the role of 11β-HSD1 in BA 
homeostasis. To the best of our knowledge, this has not yet been addressed and 
is of pivotal importance for the development of therapeutic 11β-HSD1 inhibitors 
(Rosenstock, Banarer et al. 2010; Thomas and Potter 2011). Using a model of 
liver-specific 11β-HSD1 knockout mice, we found an altered BA homeostasis. A 
significant increase of several unconjugated BAs was observed in serum and liver 
of liver-specific 11β-HSD1 knockout mice, while intrahepatic conjugated BAs 
levels were rather decreased, suggesting a reduced BA conjugating machinery 
which was confirmed by the reduced expression levels of  VLCS and VLCSH2, 
two enzymes presenting BA coenzyme A synthetase activity (Figure 4) (also 
known as BACS). On the other hand, conjugated BA levels in serum were not 
significantly changed, results which were in line with the unaltered expression 
levels of bile acid transporters. The toxicological consequences of the intrahepatic 
accumulation of BAs in liver-specific 11β-HSD1 knockout mice and also in 11β-
HSD1 full knockout mice remain to be further investigated.  Moreover, in vivo 
experiments aiming at challenging liver-specific 11β-HSD1 knockout and 11β-
HSD1 full knockout mice with lithogenic diets, the administration of cholestatic 
drugs (e.g., cyclosporine A) and bile duct ligation models will contribute to clarify 
the importance of 11β-HSD1 and consequently normal glucocorticoids 
regeneration on BA homeostasis. It is important to reinforce that 11β-HSD1 
inhibition is aimed at treating diabetic and obese patients, thus long-term and 
chronic interventions are expected. Moreover, these patients often are exposed to 
more than one therapeutic regimen; therefore the careful safety assessment of 
relevant co-treatment on BA homeostasis warrants further investigation. In 
addition, we suggest that the liver-specific 11β-HSD1 disruption might be a more 
physiologically relevant animal model to assess the effects of glucocorticoids in 
BA homeostasis, since the altered concentrations of active glucocorticoids, rather 
than the systemic concentrations are likely responsible for the dysregulation of 
BA (Figure 4). Moreover, liver-specific 11β-HSD1 knockout mice lack serious 
metabolic abnormalities, indicating that the impact of glucocorticoid and GR on 
the gluconeogenic pathway in this model is minimal. Furthermore, the role 11β-
CONCLUSIONS AND OUTLOOK 
 
96 
 
HSD1 is not only limited to GR-dependent BA homeostasis but also, on the 
conversion of the secondary 7-oxoLCA. 7-oxoLCA and particularly its taurine 
conjugated form were markedly elevated in the serum of liver-specific 11β-HSD1 
deficient mice and therefore may be potentially applied as biomarker to assess 
the efficacy of 11β-HSD1 inhibitors by the pharmaceutical industry. Importantly, 
T-7-oxoLCA was approximately 47-fold significantly enriched in serum of liver-
specific 11β-HSD1 deficient mice, whereas the concentrations of all other taurine-
conjugates BAs studied were not statistically different, suggesting its elevation is 
caused primarily due to the absence of 7-oxo reductase activity.  Nevertheless, 
the potential of 7-oxo BAs as functional biomarker has to be further evaluated in 
animals and humans using selective 11β-HSD1 inhibitors. In this context, due to 
the fact that humans mainly conjugate BAs with glycine, G-7-oxoLCA is expected 
to accumulate in the plasma.   
 
Figure 4 Possible mechanistic explanation for the effect of liver-specific 11β-
HSD1 deficiency (LKO) in BA accumulation in mice hepatocytes. Arrows indicate 
activation, X and whiskers represent blocked or pathways with reduced activity; 
question markers indicate unclear gene expression mechanisms; GBA: glyco-BA; 
TBA: tauro-BA; GCs: active glucocorticoids; BACS: BA coenzyme A synthetase; 
BAT: BA coenzyme A: amino acid N-acyltransferase; BSEP: bile-salt export 
pump; OATP4: organic anion transporters 4; FXR: Farnesoid X receptor; SHP-1: 
short heterodimer partner 1.
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